

US011567085B2

(12) United States Patent

Ge et al.

(54) PHOTO-CLEAVABLE SURFACTANTS

- (71) Applicant: Wisconsin Alumni Research Foundation, Madison, WI (US)
- Inventors: Ying Ge, Madison, WI (US); Song Jin, Madison, WI (US); Tania Guardado
 Alvarez, Madison, WI (US); Kyle
 Brown, Madison, WI (US)
- (73) Assignee: Wisconsin Alumni Research Foundation, Madison, WI (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 16/972,881
- (22) PCT Filed: Jun. 4, 2019
- (86) PCT No.: PCT/US2019/035447
 § 371 (c)(1),
 (2) Date: Dec. 7, 2020
- (87) PCT Pub. No.: WO2019/236620PCT Pub. Date: Dec. 12, 2019

(65) **Prior Publication Data**

US 2021/0253519 A1 Aug. 19, 2021

Related U.S. Application Data

- (60) Provisional application No. 62/682,027, filed on Jun. 7, 2018, provisional application No. 62/810,744, filed on Feb. 26, 2019.
- (51) Int. Cl. *G01N 33/68* (2006.01) *C07C 309/15* (2006.01)
- (52) U.S. Cl. CPC G01N 33/6848 (2013.01); C07C 309/15 (2013.01); G01N 33/68 (2013.01); G01N 33/6842 (2013.01)

(10) Patent No.: US 11,567,085 B2 (45) Date of Patent: Jan. 31, 2023

(58) Field of Classification Search CPC .. C07C 309/15; G01N 2570/00; G01N 33/68; G01N 33/6842; G01N 33/6848 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,537,432 B1*	3/2003	Schneider	G01N 27/44726
			204/450
8,697,447 B2	4/2014	Caprioli et al.	

(Continued)

OTHER PUBLICATIONS

Bradley, M., et al., Photoresponsive Surfactants in Microgel Dispersions, Langmuir, 22, pp. 101-105 (Year: 2006).* (Continued)

Primary Examiner - Yate' K Cutliff

(74) Attorney, Agent, or Firm - Leydig, Voit & Mayer, Ltd.

(57) **ABSTRACT**

The present invention provides photo-cleavable anionic surfactants, particularly 4-hexylphenylazosulfonate (Azo) and sodium 4-hexylphenylazosulfonate derivatives, which can be rapidly degraded upon UV irradiation, for top-down and bottom-up proteomics. These surfactants can effectively solubilize proteins and peptide fragments with performance comparable to sodium dodecyl sulfate (SDS) and are compatible with mass spectrometry analysis of the solubilized proteins and peptide fragments. Top-down proteomic studies using the present photo-cleavable anionic surfactants has allowed the detection of 100-fold more unique proteoforms as compared to controls and has enabled the solubilization of membrane proteins for comprehensive characterization of protein post-translational modifications. In addition, the present photo-cleavable anionic surfactants are also suitable for dissolving polypeptides in bottom-up proteomic experiments including extracellular matrix proteomics, and are suitable as a substitute for SDS in gel electrophoresis.

20 Claims, 40 Drawing Sheets



(56) References Cited

U.S. PATENT DOCUMENTS

9,816,054 B2 * 11/2017 Saveliev C11D 1/143 2018/0299463 A1 * 10/2018 Piehowski G01N 33/6848

OTHER PUBLICATIONS

Bogen, O., et al., Light-triggered conversion of non-ionic into ionic surfactants: towardscameleon detergents for 2-D gel electrophoresis, Photochemical & Photobiological Sciences, No. 11, pp. 497-499 (Year: 2012).*

Chang, Y-H. et al., New mass-spectrometry-compatible degradable surfactant fro tissue proteomics, Journal of Proteome research, No. 14, pp. 1587-1599 (Year: 2015).*

Dunkin, I.R., et al., Synthesis, characterization and applications of azo-containing phot destructible surfactants, Journal of the Chemical Society, Perkin Trans. 2, issue 9, pp. 1837-1842 (Year: 1996).* Hwang, L., et al, A family of photolabile nitroveratryl-based surfactants that self-assemble into photodegradable supramolecular structures, Langmuir, issue 32, pp. 3963-3969 (Year: 2016).*

Hwang, L., et al, A family of photolabile nitroveratryl-based surfactants that self-assemble into photodegradable supramolecular structures, Langmuir, Supporting information, issue 32, pp S1-S13 (Year: 2016).*

Dunkin et al. (1996) "Synthesis, characterization and applications of azo-containing photodestructible surfactants," Journal of the Chemical Society, Perkin Transactions 2, Issue 9, 1837-1842.

Bradley et al. (2006) "Photoresponsive Surfactants in Microgel Dispersions," Langmuir vol. 22, 101-105.

Hwang et al. (2016) "A Family of Photolabile Nitroveratryl-Based Surfactants That Self-Assemble into Photodegradable Supramolecular Structures," Langmuir vol. 32, 3963-3969.

Search Report and Written Opinion, dated Oct. 23, 2019, corresponding to International Application No. PCT/US2019/035447 (filed Jun. 4, 2019), parent of the present application, 14 pp.

Aebersold et al. (2018) "How many human proteoforms are there?" Nature Chemical Biology 14, 206-214.

Aebersold et al. (2016) "Mass-spectrometric exploration of proteome structure and function" Nature 537, 347-355.

Altelaar et al. (2013) "Next-generation proteomics: towards an integrative view of proteome dynamics" Nature Reviews | Genetics 14, 35-48.

Apweiler et al. (2004) "UniProt: The Universal Protein knowledgebase" Nucleic Acids Research 32, D115-D119.

Barrera et al. (2011) "Advances in the Mass Spectrometry of Membrane Proteins: From Individual Proteins to Intact Complexes" Annu. Rev. Biochem. 80, 247-271.

Bereman et al. (2011) "Comparison between procedures using SDS for shotgun proteomic analyses of complex samples" Proteomics, 11, 2931-2935.

Botelho et al. (2010) "Top-Down and Bottom-Up Proteomics of SDS-Containing Solutions Following Mass-Based Separation" Journal of Proteome Research, 9, 2863-2870.

Cai et al. (2016) "MASH Suite Pro: A Comprehensive Software Tool for Top-Down Proteomics" Molecular & Cellular Proteomics 15.2, 703-714.

Cai et al. (2016) "Top-down Proteomics: Technology Advancements and Applications to Heart Diseases" Expert Rev Proteomics, 13(8), 717-730.

Chang et al. (2015) "New Mass-Spectrometry-Compatible Degradable Surfactant for Tissue Proteomics" Journal of Proteome Research, 14, 1587-1599.

Chen et al. (2018) "Top-Down Proteomics: Ready for Prime Time?" Anal. Chern. 90, 110-127.

Cravatt et al. (2007) "The biological impact of mass-spectormetrybased proteomics" Nature 450, 991-1001.

Douhal et al. (1995) "Femtosecond molecular dynamics of tautomerization in model base pairs" Nature, 378, 260-263. Duan et al. (2009) "A Straightforward and Highly Efficient Precipitation/ On-Pellet Digestion Procedure Coupled with a Long Gradient Nano-LC Separation and Orbitrap Mass Spectrometry for Label-Free Expression Profiling of the Swine Heart Mitochondrial Proteome" Journal of Proteome Research, 8, 2838-2850.

Durbin et al. (2014) "Autopilot: An Online Data Acquisition Control System for the Enhanced High-Throughput Characterization of Intact Proteins" Anal. Chern. 86, 1485-1492.

Gao et al. (2018) "Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell-Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine" Circulation 137, 1717-1730.

Gregorich et al. (2014) "Top-down proteomics in health and disease: Challenges and opportunities" Proteomics 14, 1195-1210.

Kim et al. (2006) "Photocleavage of o-nitrobenzyl ether derivatives for rapid biomedical release applications" Bioorg. Med. Chern. Lett. 16, 4007-4010.

Kim et al. (2014) "A draft map of the human proteome" Nature 509, 575-581.

Loo et al. (1994) "Surfactant effects on protein structure examined by electrospray ionization mass spectrometry" Protein Science 3, 1975-1983.

Maclennan et al. (2003) "Phospholamban: A Crucial Regulator of Cardiac Contractility" Nature 4, 566-577.

Mezger et al. (1996) "Light decomposable emulsifiers: application of alkylsubstituted aromatic azosulfonates in emulsion polymerization" Progress in Organic Coatings 29, 147-157.

Prive, Gilbert G. (2007) "Detergents for the stabilization and crystallization of membrane proteins" Methods 41, 388-397.

Siuti et al. (2007) "Decoding protein modifications using top-down mass spectrometry" Nature Methods, 4(10), 817-821.

Smith et al. (2013) "Proteoform: a single term describing protein complexity" Nature Methods 10(3), 186-187.

Smith et al. (2018) "Proteoforms as the next proteomics currency" Science 359(6380), 1106-1108.

Speers et al. (2007) "Proteomics of Integral Membrane Proteomics - Theory and Application" Chern. Rev. 107, 3687-3714.

Tehrani-Bagha et al. (2007) "Cleavable Surfactants" Current Opinion in Colloid & Interface Science 12, 81-91.

Walpole et al. (2015) "Conservation of Complete Trimethylation of Lysine-43 in the Rotor Ring of c-Subunits of Metazoan Adenosine Triphosphate (ATP) Synthases" Molecular & Cellular Proteomics 14(4), 828-840.

Whitelegge et al. (1999) "Toward the bilayer proteome, electrospray ionizationmass spectrometry of large, intact transmembrane proteins" Proc. Natl. Acad. Sci. 96, 10695-10698.

Whitelegge, Julian P. "Integral Membrane Proteins and bilayer Proteomics" Anal. Chern. 85, 2558-2568 (2013).

Wientzek et al. (1991) "Isolation and Characterization of Purified Sarcoplasmic Reticulum Membranes from Isolated Adult Rat Ventricular Myocytes" J Mol Cell Cardiol 23, 1149-1163.

Wiesniewski et al. (2009) "Universal Sample preparation method for proteome analysis" Nature Methods 6(5), 359-363.

Wu et al. (2003) "The application of mass spectrometry to membrane proteomics" Nature Biotechnology 21, 262-267.

Yan et al. (2013) "Photoisomerization Quantum Yield of Azobenzene-Modified DNA Depends on Local Sequence" J. Am. Chern. Soc. 135, 8382-8387.

Yergey, James A. (1983) "A general approach to calculating isotopic distributions for mass spectrometry" International Journal of Mass Spectrometry and Ion Physics, 52, 337-349.

Yu et al. (2003) "Enzyme-Friendly, Mass Spectrometry-Compatible Surfactant for In-Solution Enzymatic Digestion of Proteins" Anal. Chern. 75, 6023-6028.

Zhou et al. (2015) "Palmitoyl acyltransferase Aph2 in cardiac function and the development of cardiomyopathy" PNAS 112(51), 15666-15671.

* cited by examiner













а



Fig. 5

b Receptor expression-enhancing protein 5







Fig. 7











Fig. 11





Fig. 13



Fig. 14







Fig. 16



Fig. 17





Fig. 19









Fig. 21 cont.



US 11,567,085 B2

Jan. 31, 2023

U.S. Patent

Sheet 23 of 40





Jan. 31, 2023

Sheet 25 of 40

Sheet 26 of 40











Biological Process



Α



Fig. 29



U.S. Patent







С



Ext. 3

D



Total Quantified Proteins: 1724





Fig. 33

E





Fig. 33 cont.



Fig. 33 cont.



8

Protein Name	Gene	Predicted TMD
NADH-ubiquinone oxidoreductase chain 5	MT-ND5	15
Cationic amino acid transporter 3	SLC7A3	14
Protein RFT1 homolog	RFT1	12
Acetyl-coenzyme A transporter 1	SLC33A1	***
Ethanolaminephosphotransferase 1	SELENOI	10











Category	Protein Name	Gene Name
Collagens	Collagen alpha-1(I) chain	COTA1
Collagens	Collagen alpha-1(VI) chain	COLGA1
Collagens	Collagen alpha-1(VII) chain	CO7A1
Collagens	Collagen alpha-1(XII) chain	COL12A1
Collagens	Collagen alpha-1(XIII) chain	COL13A1
Collagens	Collagen alpha-1(XIV) chain	COL14A1
Collagens	Collagen alpha-1(XIV) chain	K3W4R4
Collagens	Collagen alpha-1(XV) chain	COFA1
Collagens	Collagen alpha-1(XV) chain	A2AJY5
Collagens	Collagen alpha-1(XV) chain	a2ajy7
Collagens	Collagen alpha-2(I) chain	CO1A2
Collagens	Collagen alpha-2(IV) chain	CO4A2
Collagens	Collagen alpha-2(VI) chain	CO6A2
Collagens	Collagen, type VI, alpha 3 (X2)	COL6A3
Glycoproteins	Adipocyte enhancer-binding protein 1	AEBP1
Glycoproteins	EMILIN-1	EMIL1
Glycoproteins	Filtrillin-1	FBN1
Glycoproteins	Fibrillin-1	FBN1
Glycoproteins	Fibrinogen beta chain	P188
Glycoproteins	Fibrinogen gamma chain	FGG
Glycoproteins	Fibronectin	FINC
Glycoproteins	Fibulin-5	FBLNS
Glycoproteins	Lamin-B1	LMNB1
Glycoproteins	Lamin-B2	LMNB2
Glycoproteins	Laminin subunit alpha-5	LAMA5
Glycoproteins	Laminin subunit gamma-1	LAMC1
Glycoproteins	Leucine-rich HEV glycoprotein	LRG1
Glycoproteins	Nidogen-1	NID1
Glycoproteins	Periostin	POSTN
Glycoproteins	Tenascin	TENA
Glycoproteins	Thrombospondin 1	THBS1
Chicoproteine	von Willebrand factor A domain-containing	
was the order of the second second	protein 1	VWA1A
Chermentaine	von Willebrand factor A domain-containing	
	protein 3A	VWA3A
Chronostaina	von Willebrand factor A domain-containing	
wert an and a second second	protein SA	VWASA
Glycoproteins	Extracellular matrix protein FRAS1	FRASI
Glycoproteins	Vitronectin	VTNC
Glycoproteins	Insulin-like growth factor-binding protein complex acid labile subunit	GFALS
Glycoproteins	Nidogon-2	NID2
Glycoproteins	DEAD (Asp-Glu-Ala-Asp) box polypeptide 5	DDX5
Glycoproteins	Thrombospondin 1	THBS1
Glycoproteins	Papilin	PAPLN
Glycoproteins	Microfibrillar-associated protein 1A	MFAP1
Glycoproteins	Fibrinogen alpha chain	FGA
Glycoproteins	transforming growth factor, beta induced	TGFBI
2002 - 2002		

U.S. Patent

Category	Protein Name	Gene Name
Proteoglycans	Asporin	ASPN
Proteoglycans	Basement membrane-specific heparan sulfate proteoglycan core protein	HSPG2
Proteoglycans	Bigtycan	PGS1
Proteoglycans	Decorin	PGS2
Proteoglycans	Lummen	LUM
Proteoglycans	Prolargin	PRELP
Proteoglycans	Mimacan	OGN
Amiliated	Annexin A1	ANXA1
Affiliated	Annexin A2	ANXA2
Affiliated	Annexin	F8WIT2
Affiliated	Complement component 1 Q subcomponent- binding protein	CTOBP
Affiliated	Annexin AS	ANXAS
Affiliated	Annexin A4	ANXA4
Affiliated	Annexin A11	ANXA11
Affiliated	Annexin A3	ANXA3
Regulators	Protein-glutamine gamma glutamyltransferase	TGM2
Regulators	Serpin B13	SPB13
Regulators	Scrpin H1	SERPINH1
Regulators	Pigment epithelium-derived factor	SERPINF 1
Regulators	Alpha-2-macroglobulin	A2M
Regulators	kininogen 2	KNG2
Regulators	Sorpin 86	SERPINB6E
Regulators	Cathepsin D	CTSD
Regulators	Serpin 86	SERPINBS
Secreted Factors	Protein S100-A6	S100A6
Secreted Factors	Protein \$100-A8	S100A8
Secreted Factors	Protein S100-A1	S100A8

Fig. 40 continued

15

20

PHOTO-CLEAVABLE SURFACTANTS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Stage Application filed under 35 U.S.C. § 371 of International Application No. PCT/US2019/035447, filed Jun. 4, 2019, which claims priority from U.S. Provisional Patent Application No. 62/682, 027, filed Jun. 7, 2018, and U.S. Provisional Patent Appli-¹⁰ cation No. 62/810,744, filed Feb. 26, 2019, all which are incorporated by reference herein to the extent that there is no inconsistency with the present disclosure.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under GM117058 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Unlike the genome, the proteome is dynamic and highly complex mainly due to alternative splicing and post-trans- 25 lational modifications (PTMs) which modulate activity and function of proteins (Aebersold et al., 2016, Nature, 537: 347; Altelaar et al., 2012, Nature Reviews Genetics, 14: 35; and Cai et al., 2016, Expert Review of Proteomics, 13: 717-730). In the post-genomics era, a comprehensive analy- 30 sis of "proteoforms" that arise from genetic variations and PTMs, is essential for understanding biological systems at a functional level toward deciphering disease mechanisms as well as identifying key diagnostic markers and new therapeutic targets (Smith et al., 2013, Nat Methods, 10: 186-187; 35 Aebersold et al., 2018, Nature Chemical Biology, 14: 206; and Smith et al., 2018, Science, 359: 1106-1107). Conventional "bottom-up" proteomics is invaluable in the identifi-cation and quantification of the proteome as well as the elucidation of protein-protein interaction and signaling net- 40 works (Aebersold et al., 2016, Nature, 537: 347; and Cravatt et al., 2007, Nature, 450: 991). Bottom-up proteomics analyzes peptides from protein digests but does not directly identify proteoforms. Instead, the presence of proteins is inferred from identification of peptides. As a result, bottom- 45 up proteomics may be suboptimal for characterizing PTMs and sequence variants (Aebersold et al., 2018, Nature Chemical Biology, 14: 206; and Smith et al., 2018, Science, 359: 1106-1107). In contrast, top-down mass spectrometry (MS)-based proteomics, which is based on analysis of intact 50 proteins, is arguably the most powerful method to comprehensively characterize proteoforms to decipher the PTM codes together with sequence variations (Cai et al., 2016, Expert Review of Proteomics, 13: 717-730; Gregorich et al., 2014, Proteomics, 14: 1195-1210; and Siuti et al., 2007, 55 Nature Methods, 4: 817-821). However, despite its promising outlook, top-down proteomics still faces significant challenges (Gregorich et al., 2014, Proteomics, 14: 1195-1210; and Chen et al., 2018, Analytical Chemistry, 90: 110-127). 60

Protein solubility remains a major challenge in bottom-up and top-down proteomics. To effectively extract proteins from cells/tissues, surfactants (also known as detergents) are commonly included in the extraction buffer (Wisniewski et al., 2009, Nat Methods, 6: 359-362). In particular, mem-55 brane proteins, which comprise approximately one-third of the proteome and play an important role in many essential

cellular functions and account for a significant proportion of drug targets, are not soluble in aqueous solutions without the addition of surfactants because of their hydrophobic nature (Whitelegge et al., 2013, Anal Chem, 85: 2558-2568; Wu et al., 2003, Nat Biotechnol, 21: 262-267; Whitelegge et al., 1999, Proc Natl Acad Sci USA, 96: 10695-10698; and

Barrera et al., 2011, Annu Rev Biochem, 80: 247-271). Unfortunately, conventional surfactants such as sodium

dodecyl sulfate (SDS) are not compatible with MS because they greatly suppress the MS signal of proteins (Wisniewski et al., 2009, Nat Methods, 6: 359-362; Speers et al., 2007, Chem Rev, 107: 3687-3714; and Loo et al., 1994, Protein Sci, 3: 1975-1983). Therefore, an extra step is needed to remove the surfactant prior to MS analysis, which is not only time consuming, but also results in protein loss and degradation (Wisniewski et al., 2009, Nat Methods, 6: 359-362; Duan et al., 2009, J Proteome Res, 8: 2838-2850; Bereman et al., 2011, Proteomics, 11: 2931-2935; Yu et al., 2003, Anal Chem, 75: 6023-6028; and Botelho et al., 2010, J Proteome Res, 9: 2863-2870). To address these problems, it is critical to develop surfactants compatible with both top-down and bottom-up MS with the ability to effectively solubilize proteins, where the surfactant can quickly degrade into innocuous non-surfactant byproducts prior to MS analysis.

In the past years, major efforts have been dedicated in developing acid-labile surfactants, which contain an acidlabile functional group between the hydrophilic head and hydrophobic tail and thus can be degraded after incubation with acid (Chang et al., 2015, Journal of Proteome Research, 14: 1587-1599). Although various acid-labile surfactants such as RapiGest[™] (RG, Waters), ProteaseMax[™] (PM, Promega) and the recently developed MScompatible slowlydegradable surfactant (MasDeS) have been demonstrated as being effective for bottom-up proteomics, none of them have demonstrated direct compatibility with intact protein MS for top-down proteomics due to the significant signal suppression during the ionization process. Additionally, these commonly employed acid-labile surfactants require highly acidic conditions post-digestion for degradation and often require an offline clean-up step, making it difficult for fast automation. Moreover, the strong acidic degradation may cause loss of labile post-translational modifications that are not stable in acidic conditions (Zhang et al., 2015, Molecular & cellular proteomics: MCP, 14: 2441-2453). In addition, some of these acid-labile surfactants generate amine products after acid degradation that interfere with the isobaric amine-reactive tandem mass tag labeling reagents such as TMT and iTRAQ.

Therefore, an ideal MS-compatible non-acid labile surfactant that can solubilize and denature proteins and other compounds without time-consuming clean-up or desalting requirements, and thus is compatible with both top-down and bottom-up proteomics, is particularly attractive in streamlining sample preparation in proteomics. Preferably, such surfactants can be also utilized as surfactants to solubilize compounds in electrophoresis.

SUMMARY OF THE INVENTION

Bottom-up proteomics (BUP) and top-down proteomics (TDP) are powerful methods for the comprehensive characterization of PTMs, which regulate protein activity, interactions, and function. Despite their promising outlook, BUP and TDP still face many challenges such as protein solubility, particularly for membrane proteins. Unfortunately, traditional surfactants like sodium dodecyl sulfate (SDS) are known to suppress electrospray ionization (ESI) of proteins, making them incompatible with mass spectrometry (MS) analysis. The present invention describes rapidly-degradable, anionic surfactants capable of extracting a high concentration of intact protein while also being amenable to downstream MS and tandem MS (MS/MS) analysis. Also 5 described herein is a generalizable, surfactant-aided liquid chromatography (LC)-MS/MS method able to comprehensively characterize the PTMs of important membrane proteins

Distinct from the previous approaches of making acid- 10 labile surfactants, the present invention provides photocleavable surfactants which are stable under acidic conditions, but can be cleaved and degraded upon irradiation with light, especially ultraviolet (UV) radiation, before MS analysis (FIG. 1, panel a). Therefore, these surfactants will not 15 significantly interfere with MS detection of proteins. In an aspect of the invention, a library of photolabile surfactants have been designed and synthesized by inserting a photocleavable moiety in between the hydrophilic head and hydrophobic tail. Degradation via a photochemical reaction 20 wherein, has the advantage of being simple, clean (no additional reagents typically need to be added), fast, and can be easily controlled by turning on and off a suitable light source (such as a UV lamp).

In an embodiment, the present invention provides photo- 25 labile surfactants by inserting a photo-cleavable moiety in between the hydrophilic head and hydrophobic tail. In a further embodiment, O-nitrobenzyl (ONB), O-nitroveratryl (ONV), and azobenzene (AZO) groups are chosen as the photo-cleavable moieties. 30

In an embodiment, the present invention provides a photo-cleavable anionic surfactant, 4-hexylphenylazosulfonate (also referred to herein as "Azo"), which can be rapidly degraded upon UV irradiation. Azo can effectively solubilize proteins with performance comparable to sodium 35 dodecyl sulfate (SDS) and is MS-compatible. For example, after solubilization, a sample to be analyzed using mass spectrometry is exposed to UV radiation, which decomposes the Azo prior to entering the mass spectrometer. Azo-aided top-down proteomics has allowed the detection of 100-fold 40 more unique proteoforms as compared to controls and enabled the solubilization of membrane proteins for comprehensive characterization of post-translational modifications. It is believed that the surfactants of the present invention are the first MS-compatible cleavable surfactants 45 developed for top-down proteomics.

In an embodiment, the present invention provides a photo-cleavable surfactant comprising: a) hydrophilic head, b) a hydrophobic tail, and c) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic 50 tail, where the photo-cleavable moiety is able to release the hydrophilic head, release the hydrophobic tail, and/or break apart upon exposure to electromagnetic radiation. Preferably, the electromagnetic radiation is ultraviolet (UV) light. Preferably, the photo-cleavable moiety releases the hydro- 55 philic head, releases the hydrophobic tail, or degrades under light having a wavelength between 150-450 nm, between 200-400 nm, between 250-350 nm, or between 280-300 nm.

Preferably, the photo-cleavable surfactant is stable at any pH, but is especially functional at a pH range that is not 60 operable for other existing surfactants, such as acid labile surfactants. In an embodiment, the photo-cleavable surfactant is able to remain stable at a pH of 4 or lower, at a pH of 3 or lower, at a pH of or lower 2, or at a pH of 1 or lower. Conventional acid labile surfactants typically hydrolyze at a 65 pH of approximately 2-3. In an embodiment, the photocleavable surfactants of the present invention, such as the

Azo surfactant, are stable at any pH and photo degradation is optimal at low pH (~2) with an organic solvent. Under aqueous conditions, pH has little or no effect on the surfactant. This makes surfactants of the present invention well suited for both offline and online LC/MS analysis of proteins, which commonly utilize acid in the electrospray solution and mobile phases. Moreover, many proteins need to be extracted under acidic conditions, which renders conventional rapidly acid-labile surfactants ineffective.

In an embodiment, the photo-cleavable surfactant has the formula:

$$Na^+ O = O = R4_{(m)} N = N - R1 - R2 - R3$$

- R1 is a substituted or unsubstituted aryl group having from 4 to 18 carbon atoms, preferably 5 to 7 carbon atoms:
- R2 is a substituted or unsubstituted alkylene or alkenylene group having from 2 to 18 carbon atoms, preferably 4 to 8 carbon atoms;
- R3 is a substituted or unsubstituted alkyl, alkenyl, or aryl group having from 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms;
- R4 is a substituted or unsubstituted alkylene or alkenylene group having from 1 to 5 carbon atoms; and

m is an integer selected from 1 and 0.

In an embodiment, the photo-cleavable surfactant has the formula:



where n is an integer selected from 2 to 30. Preferably, n is an integer selected from 2 to 20, an integer selected from 4 to 15, or an integer selected from 6 to 12. Preferably, n is 6, 8, 10 or 12. In an embodiment, the photo-cleavable surfactant is sodium 4-hexylphenylazosulfonate.

In an embodiment, the photo-cleavable surfactant has the formula:



wherein

- R1 is a substituted or unsubstituted aryl group having from 6 to 18 carbon atoms, preferably 5 to 8 carbon atoms:
- R2 is a substituted or unsubstituted alkylene or alkenylene group having from 2 to 18 carbon atoms, preferably 2 to 8 carbon atoms;
- R3 is a substituted or unsubstituted alkyl, alkenyl, or aryl group having from 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms; and

30

65

R4 is a substituted or unsubstituted alkylene or alkenylene group having from 1 to 8 carbon atoms, preferably 5 to 8 carbon atoms.

In an embodiment, the photo-cleavable surfactant has the formula:



where n is an integer selected from 2 to 30. Preferably, n is an integer selected from 2 to 20, an integer selected from 4 to 15, or an integer selected from 4 to 12. Preferably, n is 4, 6 or 10.

In an embodiment, the photo-cleavable surfact ant has the $\ ^{20}$ formula:



wherein

- R1 is a substituted or unsubstituted aryl group having from 6 to 18 carbon atoms, preferably 5 to 8 carbon atoms;
- R2 is a substituted or unsubstituted alkylene or alkenylene group having from 2 to 18 carbon atoms, preferably 2 to 8 carbon atoms;
- R3 is a substituted or unsubstituted alkyl, alkenyl, or aryl group having from 1 to 18 carbon atoms, preferably 1 to 3 carbon atoms; and
- R4 is a substituted or unsubstituted alkylene or alkenylene group having from 1 to 8 carbon atoms, preferably 5 to 8 carbon atoms.

In an embodiment, the photo-cleavable surfactant has the formula:



where n is an integer selected from 2 to 30. Preferably, n is an integer selected from 2 to 20, an integer selected from 4 60 to 15, or an integer selected from 6 to 12. Preferably, n is 6, 8 or 10.

In an embodiment, the photo-cleavable surfactant is stable at a pH of 7 or greater, a pH of 6 or greater, a pH of 5 or greater, a pH of 4 or greater, or a pH of 3 or greater.

In an embodiment, the present invention provides a method of solubilizing a compound comprising the steps of:

a) mixing the compound with a photo-cleavable surfactant in a solution until the compound is dissolved in the solution; and b) exposing the solution containing the photo-cleavable surfactant and dissolved compound to electromagnetic radiation, thereby cleaving the photo-cleavable moiety, wherein the photo-cleavable surfactant comprises: i) hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail. Preferably, the compound is a protein or a polypeptide. In an embodiment, the compound is a membrane protein, including but not limited to receptor proteins (e.g., beta-adrenergic receptors) or ion channel proteins. In an embodiment, the compound is an extra cellular matrix protein (ECM).

Optionally, the method further comprises performing mass spectrometry (MS) analysis on a portion of the irradiated solution containing the compound, such as part of an online liquid chromatography-mass spectrometry (LC/MS) experiment. In an embodiment, after dissolving the compound in the solution containing the photo-cleavable surfactant, a chromatography step is performed on the solution in order to purify or separate the components in the solution. The portion or fraction of the solution which contains the dissolved compound is exposed to the electromagnetic radiation before injecting or spraying the dissolved compound into the mass spectrometer. Optionally, the photodegradation occurs after chromatography separation of proteins before spraying into the mass spectrometer, as the experiments happen in a real time.

Alternatively, photodegradation of the photo-cleavable surfactant occurs in the mass spectrometer during ultraviolet photo-dissociation (UVPD). UVPD is becoming a powerful tandem mass spectrometry (MS/MS) tool for comprehensive analysis of proteins (Brodbelt et al., 2014, Chem. Soc. Rev., 43(8): 2757-2783), and is compatible with current mass spectrometers. For example, the Thermo Orbitrap Lumos is a popular proteomic instrument that can be currently equipped with a 213 nm UV laser.

Preferably, the solution containing the photo-cleavable surfactant and dissolved compound is exposed to ultraviolet (UV) light. Preferably, the light has a wavelength between 150-450 nm, between 200-400 nm, between 250-350 nm, or between 280-300 nm. In an embodiment, the solution containing the photo-cleavable surfactant and dissolved com-45 pound is exposed to the electromagnetic radiation for a time period between 10 and 500 seconds, preferably between 15 and 400 seconds, between 20 and 300 seconds, between 25 and 200 seconds, or between 30 and 150 seconds.

The solution comprises an organic solvent, aqueous solvent, or combinations thereof. Optionally, the solution also comprises 10% or less of an acid or reducing agent. Alternatively, the solution does not contain any additional acids or reducing agents. The solution also comprises 1% or less of the photo-cleavable surfactant, preferably 0.5% or less of the photo-cleavable surfactant, preferably 0.1% or less of the photo-cleavable surfactant. In an embodiment, the solution comprises 70% or more of an organic solution, 5% or less of an acid, and 0.1% or less of the photo-cleavable surfactant.

The optimal formulation depends on the proteins and protein families being solubilized. In an embodiment, the solution comprises 20-80% organic solvent, 0.1-5% acid, and 0.1-1% surfactant. Preferred organic solvents include, but are not limited to, acetonitrile, methanol, and isopropanol (IPA). The solution may also comprise tri(2-carboxyethyl) phosphine hydrochloride (TCEP) so as to reduce or minimize oxidative modification of proteins during analysis. Optionally an acid, such as formic acid, is added to speed up

degradation of the photo-cleavable moiety. In an embodiment, the solution comprises at least 30% organic solvent (such as IPA) in order to avoid salt formation. In an embodiment, the solution comprises 40% IPA or (IPA:ACN 1:1), 1% formic acid, 100 mM TCEP (avoid oxidation), and 5 0.1-0.2% of the photo-cleavable surfactant.

In an embodiment, the photo-cleavable surfactant of the method a formula selected from the following:



and combinations thereof, where n is an integer selected from 2 to 30. Preferably, n is an integer selected from 2 to 20, an integer selected from 4 to 15, or an integer selected 35 from 4 to 12. Preferably, n is 4, 6, 8 or 10. Preferably, the photo-cleavable surfactant is sodium 4-hexylphenylazosulfonate.

Additional advantages of certain embodiments of the present invention include: (1) fast and scalable surfactant 40 synthesis (two-step synthesis with recrystallization for purification); (2) rapid surfactant degradation at ambient temperature with UV irradiation (30-150 s with visible color change); (3) operating conditions that allow for retained protein solubility post-degradation; (4) compatibility with 45 direct ESI-MS and LC-MS analysis after photo degradation; (5) extraction of a high concentration of proteins with performance comparable to SDS; and (6) the ability to solubilize proteins that are typically difficult to solubilize, notably membrane proteins, enabling their characterization 50 end and having one or more liquid buffers, wherein the one by mass spectrometry with minimal additional purification steps.

While aspects of the present invention provide improvements over surfactants and methods used in conjunction with top-down proteomics, it should be noted the present 55 invention is useful for bottom-up proteomics as well. In bottom-up proteomics, proteins are solubilized and digested into smaller polypeptides, and the mixtures of polypeptides are analyzed together. The present methods and surfactants can be utilized to improve solubility of proteins and facili- 60 tate the extraction of proteins from tissues, cells etc. for both top-down proteomics and bottom-up proteomics.

In an embodiment, the photo-cleavable surfactants of the present invention are provided in a method for analyzing a polypeptide comprising the steps of:

a) mixing the polypeptide with a photo-cleavable surfactant in a solution until the compound is dissolved in the

solution, wherein the polypeptide has a molecular weight of 100 daltons or more, and wherein the photo-cleavable surfactant comprises: i) a hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail;

b) exposing the solution containing the photo-cleavable surfactant and dissolved compound to electromagnetic radiation, thereby decomposing the photo-cleavable moiety; and

- c) performing mass spectrometry (MS) analysis on a portion of the irradiated solution containing the polypeptide. In an embodiment, the photo-cleavable surfactants of the present invention are provided in a method for analyzing a polypeptide comprising the steps of:
- a) fragmenting or digesting the polypeptide into a plurality of fragments;

b) mixing the plurality of fragments with a photo-cleavable surfactant in a solution until a portion of the plurality off fragments is dissolved in the solution, wherein the photocleavable surfactant comprises: i) a hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail;

c) exposing the solution containing the photo-cleavable

surfactant and dissolved fragments to electromagnetic radia-25 tion, thereby decomposing the photo-cleavable moiety; and

d) performing mass spectrometry (MS) analysis on a portion of the irradiated solution containing the dissolved fragments

These analytical methods optionally further comprise 30 separating components in the solution using a chromatography step and exposing the solution containing the dissolved fragments to electromagnetic radiation before injecting the dissolved fragments into a mass spectrometer. In further embodiments, the solution containing the dissolved fragments is exposed to electromagnetic radiation within a mass spectrometer during ultraviolet photo-dissociation (UVPD).

Additionally, the surfactants and methods described herein can be utilized to improve solubility of compounds in a wide range of biological and chemical applications, including applications that typically involve denaturing surfactants. For example, in an embodiment of the invention, the present surfactants are suitable as general alternatives to sodium dodecyl sulfate (SDS).

In an embodiment, the photo-cleavable surfactants of the present invention are provided in a method for separating components in a sample solution using electrophoresis, the method comprising the steps of:

a) providing a porous gel having a first end and a second or more liquid buffers are able to conduct an electric current across the gel;

b) disposing the sample solution in the first end of the gel, wherein the sample solution further comprises a photocleavable surfactant comprising: i) a hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail, and wherein the sample solution and the one or buffers do not comprise a significant amount of sodium dodecyl sulfate (SDS) or urea; and

c) applying an electric current across the first and second end of the porous gel, wherein the components in the sample solution will move from the first end of the porous gel toward the second end of the porous gel.

The use of one or more photo-cleavable surfactants of the present invention as substitute for SDS is particularly useful when the sample solution comprises one or more polypeptides. Preferably, the porous gel is a polyacrylamide gel and the sample solution further comprises a tracking dye or stain. The electrophoresis process may further have less than 0.1%sodium dodecyl sulfate (SDS) or urea in the sample solution and the one or more buffers, preferably no sodium dodecyl 5 sulfate (SDS) or urea.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1—Synthesis and characterization of a photo-cleav- 10 able anionic surfactant, 4-hexylphenylazosulfonate (Azo). Panel (a), scheme illustrating the use of Azo in solubilizing proteins, followed by rapid degradation with UV irradiation, and MS analysis of the intact proteins. Note that the molecules are not drawn to scale. Panel (b), degradation of Azo 15 into 4-hexylphenol, 4-hexylbenzene, nitrogen, and hydrogen sulfate. Panel (c), synthetic scheme for Azo.

FIG. 2—Panel (a), UV-Vis spectra of Azo (0.1%) degradation as a function of time showing that Azo can be rapidly degraded upon UV irradiation at ambient temperature. Pan- 20 els (b) and (c), SDS-PAGE analysis (panel c) and Pierce[™] 660 nm protein assay with ionic detergent compatibility for the evaluation (panel b) of effectiveness of surfactant aided protein extractions (E3) following the initial HEPES buffer extractions (E1 & E2) to deplete the cytosolic proteins. An 25 equal volume of each extract was used. Panel (d), electrospray ionization (ESI)-MS analysis of Ubi with 0.1% surfactant showed the MS-compatibility of surfactants. The mass spectra were normalized to an intensity of 1.7E6. NS, no surfactant (serving as controls); Azo; SDS, sodium 30 dodecyl sulfate; DDM, n-dodecyl β-D-maltoside; MaSDeS, MS-compatible slowly degradable surfactant.

FIG. 3-Photo-cleavable Azo-enhanced top-down proteomics. Panel (a), schematic depicting sequential tissue extraction procedures. Proteins from cardiac tissue were 35 extracted using HEPES buffer (2x) to deplete the cytosolic proteins, followed by an extraction using NH4HCO3 solution with or without 0.5% Azo. Panel (b), comparison of the total ion chromatogram (TIC) of equal injection volumes of the final cardiac extraction with or without 0.5% Azo. Panel 40 (c), comparison of detected proteoforms in a single RPLC-MS run of proteins extracted with or without Azo. Panel (d), intact proteoform mass map from cardiac tissue extraction with Azo or without Azo (NS).

cardiac tissue in Azo-enhanced top-down proteomics combining 3 RPLC-MS/MS runs.

FIG. 5-Photo-cleavable Azo-enabled membrane proteomics. MS and MS/MS analysis of representative membrane proteins from Azo-aided extraction of cardiac tissue. 50 Panel (a), phospholamban (PLN) and palmitoylated-phospholamban with palmitoylation identified at cysteine 37 residue. Panel (b), receptor expression-enhancing protein 5.

FIG. 6-Complete analysis of ATP synthase subunit proteins from cardiac tissue. Overall all the ATP synthase 55 subunits (e, f, g, ATP6, ATPS, DAPIT, C, 6.8PL) were detected that exist in the inner membrane space (IMS) as well as the subunits (α , β , b, ϵ , δ , OCSP, F6, d, γ) located in the mitochondrial matrix. The schematic of ATP synthase was modified based on a previous publication by He et al. 60 (Proc. Natl. Acad. Sci., 2018, 115(12): 2988-2993)

FIG. 7-Negative ion ESI-FT-ICR mass spectrum of 4-hexylphenylazosulfonate (Azo).

FIG. 8—¹H-NMR spectrum of Azo (c=6). A Hermes-Varian Mercury Plus 300 operating at 300 MHz was utilized 65 for ¹H-NMR spectroscopy with chemical shifts reported as ppm (parts per million). H NMR: δ 7.64 (2H, dd, -Ar-

H), 7.37 (2H, d, —Ar—H), 2.67-2.48 (2H, m, —Ar—CH₂), 1.61 (2H, t, —Ar—CH₂CH₂), 1.28 (6H, t, —(CH₂)₃) 0.086 (3H, t, --(CH₂)₃--CH₃).

FIG. 9-Polyacrylamide gel electrophoresis (PAGE) using Azo (panels a and b) and SDS (panels c and d). Azo-PAGE analysis of (panel a) 2.5 µg bovine serum albumin (BSA), β -casein, and ribonuclease A (RNase A), and (panel b) myofilament cardiac tissue protein extract with Coomassie blue staining. SDS-PAGE analysis of (panel c) 2.5 μ g BSA, β -Casein, and RNase A, and (panel d) myofilament cardiac tissue protein extract with Coomassie blue staining. M: molecular weight ladder; S: standard proteins, T, myofilament protein extract.

FIG. 10-Evaluation of surfactant-aided extraction of cardiac membrane proteins using western blot analysis. Western blot analysis of common cardiac membrane proteins, cadherin, sodium potassium adenosine triphosphate (Na-K ATPase), voltage-dependent anion-selective channel (VDAC), phospholamban (PLN), and mitochondrial import receptor subunit (TOM20). 12.5% SDS-PAGE was used to resolve 20 µL of lysate extracted using 25 mM NH4HCO3 without surfactant (NS), or with surfactant, 4-hexylphenylazosulfonate (Azo), sodium dodecyl sulfate (SDS), dodecyl β-D-maltoside (DDM), and MS-compatible degradable surfactant (MaSDeS), respectively. The addition of Azo in the buffer successfully aided in the extraction of these five important integral membrane proteins in cardiac tissue, with performance comparable to SDS and MaSDeS.

FIG. 11-Effects of solvent conditions on Azo degradation kinetics. Azo (0.1%) was degraded in different solvent conditions; panel (a) water, panel (b) 1% formic acid in water, panel (c) IPA, panel (d) 1% formic acid in IPA, panel (e) 2-ME in IPA, panel (f) 1% formic acid in 50:50 mixture of water:IPA, respectively, to probe their effects on degradation kinetics. Overall the surfactant degraded rapidly particularly in the presence of organic solvent at low pH (panels d and f).

FIG. 12—Effects of exposure to ultraviolet (UV) light on selected proteins. Ubi (panel a), RNase A (panel (b), and BSA (panel c) were irradiated for 3 min prior to direct injection into the MS. Overall no change was observed after irradiation. The mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer.

FIG. 13—The effect of addition of reducing agents during FIG. 4—Subcellular location of proteins identified in 45 Azo degradation. A standard protein, Cytc, was panel (a) incubated on ice, panel (b) incubated on room temperature (RT), panel (c) irradiated at RT, panel (d) irradiated at RT with Azo, panel (e) irradiated at RT with Azo and 50 mM DTT, panel (f) irradiated at RT with Azo and 50 mM 2-ME, and panel (g) irradiated at RT with Azo and 50 mM TCEP before LC-MS analysis. All the incubations were done for 3 min. Overall TCEP alleviated oxidative modification observed when incubated at RT or by exposing it to the radicals generated upon photolysis of the surfactant. Mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer.

> FIG. 14-The presence of methionine during Azo degradation alleviated oxidative modification. A standard protein, ubiquitin (Ubi), was panel (a) incubated on ice, panel (b) irradiated at room temp with Azo (0.1%), panel (c) irradiated at room temp with Azo (0.1%) and Methionine (33 mM), panel (d) irradiated at room temp with Azo (0.1%) and TCEP (10 mM). Mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer.

> FIG. 15-Effect of Azo on relative quantitation by LC-MS using HEPES Cardiac Extract. A sample of cardiac proteins extracted using HEPES buffer was analyzed by

LCMS as well as a sample spiked with Azo (0.2%). Panel (a), total ion chromatogram for HEPES Cardiac Extract and Cardiac Extract+Azo. Extracted ion chromatograms of the top 5 charges states were performed and the area under the curve calculated for panel (b) myoglobin, panel (c) malate ⁵ dehydrogenase, and panel (d) cardiac troponin C. Error bars represent standard error of the mean for 3 injection replicates. Mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer.

FIG. 16-Evaluation of surfactant-aided extraction of cardiac tissue using SDS-PAGE and protein assay. Swine heart proteins were extracted using 0.5% surfactant in 25 mM NH₄HCO₃ following a HEPES extraction to remove water-soluble proteins. Panel (a), MS-compatible degrad-15 able surfactant (MaSDeS), ProteaseMax[™] (PM). RapiGest[™] (RG), 25 mM NH4HCO3 with no surfactant (NS), sodium dodecyl sulfate (SDS), 4-hexylphenylazosulfonate (Azo), Octyl β-D-glucopyranoside (OG), dodecyl β -D-maltoside (DDM), digitonin (DGT) were tested. Panel 20 (b), protein assay used to assess the extracted protein concentration facilitated by each surfactant.

FIG. 17—MS-compatibility evaluation of Azo as compared to commonly used surfactants. 0.1% surfactant was added to ubiquitin in 25 mM NH₄HCO₃ solution and ana-25 lyzed by high-resolution mass spectrometry and compared to controls with no surfactant (NS). Surfactants including MS-compatible slowly-degradable surfactant (MaSDeS), ProteaseMaxTM (PM)1, RapiGestTM (RG), sodium dodecyl sulfate (SDS), 4-hexylphenylazosulfonate (Azo), Octyl β -D-30 glucopyranoside (OG), dodecyl β -D-maltoside (DDM), and digitonin (DGT) were tested. The mass spectra were collected on a Bruker 12 T FTICR mass spectrometer and normalized to the maximum intensity in the NS (control) spectrum of 8E10. 35

FIG. 18-Comparison of surfactant effect on LC-MS analysis of cardiac tissue lysate. Cardiac proteins extracted using NH₄HCO₃ buffer either without surfactant (NS, serve as control) or with surfactant (0.1%). The surfactants tested here include MS-compatible slowly-degradable surfactant 40 (MaSDeS), ProteaseMax[™] (PM), RapiGest[™] (RG, also known as ALS), sodium dodecyl sulfate (SDS), 4-hexylphenylazosulfonate (Azo), Octyl β-D-glucopyranoside (OG), dodecyl β-D-maltoside (DDM), and digitonin (DGT). The acid- and photo-cleavable surfactants were degraded under 45 acid or UV respectively. All the samples were buffer exchanged and analyzed by LC-MS. Mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer. Panel (a), total ion chromatogram comparing the MS signal of cardiac tissue lysate in the presence of different surfac- 50 tants compared to control. Panel (b), total ion chromatogram comparing the MS signal of cardiac tissue lysate in the presence of different anionic surfactants. Panel (c), representative mass spectra from proteins eluted at 18-19 min showing multiple co-eluting proteins. Intensity normalized 55 to 1.36E4. Panel (d), representative mass spectra of a protein eluted from 20-21 min Intensity normalized to 1.62E5.

FIG. **19**—Comparison of cardiac tissue extraction using MS-compatible NH_4HCO_3 with or without Azo in a single RPLC/MS run. Panel (a), MS total ion chromatogram with 60 representative proteins: panel (b) enigma homolog 2 (ENH2), panel (c) troponin I (cTnI), panel (d) calsarcin-1 (CS-1), panel (h) alpha-crystallin b chain (CRYAB), panel (i) cytochrome c oxidase subunit 4 isoform 1 (COX4II), and panel (j) NADH dehydrogenase Fe—S protein 4 (NDUSF4). 65 These proteins were detected in the Azo-extraction but not detected in the control without Azo. Mass spectra were

collected on a Bruker maXis II Q-TOF mass spectrometer. NS: no surfactant, such as in panels (e), (f), and (g) serving as controls.

FIG. 20—Azo-enable membrane proteomics from cardiac tissue. Panel (a), SDS-PAGE analysis of cardiac proteins extracted first in a high salt buffer twice and labeled as extraction 1 (E1) and extraction 2 (E2), respectively, followed by a third extraction (E3) in 25 mM NH₄HCO₃ with either no surfactant (NS) or 0.5% Azo. Panels (b-h), represented deconvoluted mass spectra from LC-MS analysis using equal volume of extract (NS and Azo) confirming the enhancement of membrane protein signal that occurs by adding Azo to the extraction buffer. Panel (b), cvtochrome c oxidase subunit 4 isoform 1. Panel (c), cytochrome c oxidase subunit 7C. Panel (d), phospholamban. Panel (e), NADH dehydrogenase [ubiquinone] iron-sulfur protein 6. Panel (f), succinate dehydrogenase cytochrome b560 subunit. Panel (h), ATP synthase subunit c. Mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer. Each spectrum was normalized to the intensity value corresponding to protein signal intensity in the Azo extraction

FIG. 21-Representative membrane proteins identified from human embryonic kidney (HEK) Cells. Panel (a), SDS-PAGE analysis of HEK cell proteins extracted with a Tris buffer and labeled as extraction 1 (E1). The pellets were next extracted with NH₄HCO₃ and labeled as extraction 2 (E2). Finally a third extraction (E3) was performed using 25 mM NH₄HCO₃ with either no surfactant, E3 (NS), or 0.5% Azo, E3 (Azo). Representative membrane proteins identified in the E3 (Azo) extract by top-down proteomics include panel (b) ATP synthase subunit g, panel (c) eukaryotic translation initiation factor 5A, panel (d) dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4, panel (e) protein transport protein Sec61 subunit gamma, panel (f) mitochondrial import receptor subunit Tom22, panel (g) ATP synthase subunit c, panel (h) dolichol phosphate-mannose biosynthesis regulatory protein, panel (i) vacuolar ATPase assembly integral membrane protein VMA21, panel (j) B-cell receptor-associated protein 31, panel (k) V-type proton ATPase 16 kDa proteolipid subunit, and panel (1) ADP/ATP translocase 2. Mass spectra were collected on a Bruker maXis II Q-TOF mass spectrometer.

FIG. **22**—Identification of succinate dehydrogenase cytochrome b560 subunit by top-down proteomics enabled by Azo. Panel (a), intact mass spectrum of succinate dehydrogenase cytochrome b560 acquired with high mass accuracy using a Bruker maXis II Q-TOF mass spectrometer. Panel (b), sequence fragmentation (CID) map. Shaded regions indicate the three transmembrane domains. Panel (c), represented fragments used to confidently identify the protein

FIG. 23—Localization of palmitoylation (palm) on phospholamban (PLN) by online LC-MS/MS with CID. Panel (a), high-accuracy measurement of PLN and its highly abundant palmitoylated proteoform acquired on a Bruker maXis II Q-TOF mass spectrometer; panel (b), CID fragmentation map of both PLN and palmPLN with designated regions designating the transmembrane domain; panel (c) representative ions for the palmPLN showing the localization of the palmitoylation to the cysteine 36 residue. Circles show theoretical isotopic distribution

FIG. **24**—Localization of trimethylation on ATP synthase c by online LC-MS/MS with CID. Panel (a), high-accuracy measurement of ATP synthase subunit c acquired on a Bruker maXis II Q-TOF mass spectrometer; panel (b), CID fragmentation map with designated regions designating the two transmembrane domains; panel (c), representative ions measured with high mass accuracy representing the trimethylated (Me3) ATP synthase c. Circles show theoretical isotopic distribution.

FIG. 25-Illustration showing top-down MS-compatibility and protein solubility experiments with Azo. These 5 experiments show that Azo effectively solubilizes proteins but also is top-down MS compatible.

FIG. 26-Whole-tissue cardiac extraction reproducibility using Azo in a bottom-up proteomic experiment. Blot analysis of extractions from 6 swine were performed using $0.5\%_{-10}$ Azo.

FIG. 27-Base peak chromatogram overlap of three whole-tissue cardiac extractions in a bottom-up proteomic experiment.

FIG. 28—Gene ontology for protein identified from swine 15 cardiac tissue using the Azo platform in a bottom-up proteomic experiment.

FIG. 29-Azo enabled digestion in a bottom-up proteomic experiment. Panel (A), BSA digestion monitored by SDS-PAGE in the presence of 0, 0.05, 0.1% Azo. Panel (B), 20 Extracellular Matrix (ECM) bottom-up proteomics. Myoglobin digestion monitored by LCMS. Extraction ion chromatogram of intact myoglobin shows increased digestion in the presence of Azo.

FIG. 30-High-throughput workflow for an Azo-aided bottom-up proteomic experiment. 25

FIG. 31-Panel (A), simplified workflow for an Azoaided bottom-up proteomic experiment. Panel (B) UV-Vis spectrum for Azo highlighting maximal absorbance at 305 nm. Panel (C), UV-Vis spectrum monitoring the rapid degradation of Azo (0.1% in water) as a function of irradiation 30 time with a 100 W mercury lamp. Panel (D), degradation of Azo by UV irradiation as previously described 36. Panel (E), digestion of myoglobin [1-h in Azo (0-0.2%)] was monitored by SDS-PAGE, stained with Coomassie blue, and LC-MS with an Impact II Q-TOF mass spectrometer. 35 Extraction ion chromatogram of intact myoglobin shows increased digestion rate in the presence of Azo. Panel (F), myoglobin digestion using trypsin in the presence of 0, 0.05, 0.1. and 0.2% Azo.

FIG. 32-HEK293T cells were lysed with Azo. Panel (A), 40 SDS-PAGE analysis demonstrates consistent extraction profiles across three biological replicates. Two aliquots were taken from each exaction and digested overnight (ON) or for 1 h. After LC-MS and MaxQuant label-free quantification a high degree of overlap was observed for both the (panel B) 45 ON and (panel C) 1 h biological replicates. Similarly, (panel D) 1401 of the 1724 combined quantifiable proteins were observed in both digestion methods. Venn diagrams generated using Venny 2.1.

FIG. 33-Panel (A), SDS-PAGE visualization of protein 50 extracted from swine myocardium. 1.1, 1.2, 1.3 represent extraction replicates (n=3) and 1.1-1.3, 2, 3 represent biological replicates (n=3). Panel (B), overlap of identified genes for tissue extraction replicates from the same biological sample (extraction from tissue from animal 1, n=3). 55 Panel (C), overlap of identified genes for biological replicates (extract from different animals, n=3). Panel (D), overlap of identified genes for digestion replicates (digestion from extract 1.3, n=3). Panel (E), GO analysis for biological processes. Panel (F), GO analysis for molecular function. 60 GO analysis was performed using Panther software.

FIG. 34—Azo was used for whole tissue extraction or to solubilize the protein pellet after cloud point enrichment. Panel (A), plot of the predicted number of transmembrane domains for identified proteins. Overall 286 new identifica- 65 tions were observed after enrichment demonstrating Azo's ability to solubilize hydrophobic proteins. Panel (B), table of

representative membrane proteins with a high number of transmembrane domains that were solubilized by Azo.

FIG. 35-Myoglobin was digested with trypsin in 0% (top) or 0.1% (bottom) Azo for 1 hr. The sample was directly infused into a Bruker 12T solariX™ FTICR. Intact myoglobin signal (indicated by circles) was observed with trypsin alone without Azo whereas complete digestion was observed in the presence of Azo. Overall, no identification was obtained for the digestion without surfactant. In contrast, 89% sequence coverage was achieved using peptide mass fingerprinting when digestion was performed in the presence of Azo.

FIG. 36-Insulin, myoglobin, and carbonic anhydrase were digested using trypsin in the presence of 0, 0.1, and 0.2% Azo. The presence of intact protein was monitored by LC-MS using a maXis II ETD Q-TOF. Extracted ion chromatograms of intact proteins show increased digestion rate in the presence of Azo.

FIG. 37-High-throughput workflow for Azo-aided

FIG. 38—Whole-tissue ECM extraction reproducibility using Azo. Extractions from 6 tumor aliquots decellularized using Triton (#1-3) or LiCl extraction buffers (#1-3), following by extraction with 0.5% Azo (#1-6).

FIG. 39—Time-course for trypsin digestion of Sus scrofa Azo extraction. Mascot Total Protein Identification (ID) and ECM IDs after 1, 2, 4 hour and overnight trypsin digestion. There was no appreciable difference in protein IDs across time points.

FIG. 40-ECM proteins identified in proteomic analysis of PyVT mouse. 71 ECM proteins were identified.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

The terms "peptide" and "polypeptide" are used synonymously in the present disclosure, and refer to a class of compounds composed of amino acid residues chemically bonded together by amide bonds (or peptide bonds). Peptides are polymeric compounds comprising at least two amino acid residues or modified amino acid residues. Peptides include compositions comprising a few amino acids and include compositions comprising intact proteins or modified proteins. Modifications can be naturally occurring or non-naturally occurring, such as modifications generated by chemical synthesis. Modifications to amino acids in polypeptides include, but are not limited to, phosphorylation, glycosylation, lipidation, prenylation, sulfonation, hydroxylation, acetylation, methionine oxidation, alkylation, acylation, carbamylation, iodination and the addition of cofactors. Peptides include proteins and further include compositions generated by degradation of proteins, for example by proteolytic digestion. Peptides and polypeptides may be generated by substantially complete digestion or by partial digestion of proteins. Identifying or sequencing a peptide refers to determination of is composition, particularly its amino acid sequence, and characterization of any modifications of one or more amino acids comprising the peptide or polypeptide.

"Protein" refers to a class of compounds comprising one or more polypeptide chains and/or modified polypeptide chains. Proteins may be modified by naturally occurring processes such as post-translational modifications or cotranslational modifications. Exemplary post-translational modifications or co-translational modifications include, but are not limited to, phosphorylation, glycosylation, lipidation, prenylation, sulfonation, hydroxylation, acetylation, methionine oxidation, the addition of cofactors, proteolysis, and assembly of proteins into macromolecular complexes. Modification of proteins may also include non-naturally 5 occurring derivatives, analogues and functional mimetics generated by chemical synthesis. Exemplary derivatives include chemical modifications such as alkylation, acylation, carbamylation, iodination or any modification that derivatizes the protein. Proteins of the present invention may 10 be derived from sources, which include but are not limited to cells, cell or tissue lysates, cell culture medium after cell growth, whole organisms or organism lysates or any excreted fluid or solid from a cell or organism.

"Fragment" refers to a portion of molecule, such as a 15 peptide. Fragments may be singly or multiple charged ions. Fragments may be derived from bond cleavage in a parent molecule, including site specific cleavage of polypeptide bonds in a parent peptide. Fragments may also be generated from multiple cleavage events or steps. Fragments may be a 20 truncated peptide, either carboxy-terminal, amino-terminal or both, of a parent peptide. A fragment may refer to products generated upon the cleavage of a polypeptide bond, a C-C bond, a C-N bond, a C-O bond or combination of these processes. Fragments may refer to products formed 25 by processes whereby one or more side chains of amino acids are removed, or a modification is removed, or any combination of these processes. Fragments useful in the present invention include fragments formed under metastable conditions or result from the introduction of energy to 30 the precursor by a variety of methods including, but not limited to, collision induced dissociation (CID), surface induced dissociation (SID), laser induced dissociation (LID), electron capture dissociation (ECD), electron transfer dissociation (ETD), or any combination of these methods or 35 any equivalents known in the art of tandem mass spectrometry. Fragments useful in the present invention also include, but are not limited to, x-type fragments, y-type fragments, z-type fragments, a-type fragments, b-type fragments, c-type fragments, internal ion (or internal cleavage ions), immo- 40 nium ions or satellite ions. The types of fragments derived from a parent analyte, such as a polypeptide analyte, often depend on the sequence of the parent, method of fragmentation, charge state of the parent precursor ion, amount of energy introduced to the parent precursor ion and method of 45 delivering energy into the parent precursor ion. Properties of fragments, such as molecular mass, may be characterized by analysis of a fragmentation mass spectrum.

The term "alkyl" refers to a monoradical of a branched or unbranched (straight-chain or linear) saturated hydrocarbon 50 and to cycloalkyl groups having one or more rings. Alkyl groups as used herein include those having from 1 to 30 carbon atoms, preferably having from 1 to 12 carbon atoms. Alkyl groups include small alkyl groups having 1 to 3 carbon atoms. Alkyl groups include medium length alkyl 55 groups having from 4-10 carbon atoms. Alkyl groups include long alkyl groups having more than 10 carbon atoms, particularly those having 10-30 carbon atoms. Cycoalkyl groups include those having one or more rings. Cyclic alkyl groups include those having a 3-, 4-, 5-, 6-, 7-, 60 8-, 9-, 10-, 11- or 12-member carbon ring and particularly those having a 3-, 4-, 5-, 6-, or 7-member ring. The carbon rings in cyclic alkyl groups can also carry alkyl groups. Cyclic alkyl groups can include bicyclic and tricyclic alkyl groups. Alkyl groups are optionally substituted. Substituted 65 alkyl groups include among others those which are substituted with aryl groups, which in turn can be optionally

16

substituted. Specific alkyl groups include methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, s-butyl, t-butyl, cyclobutyl, n-pentyl, branched-pentyl, cyclopentyl, n-hexyl, branched hexyl, and cyclohexyl groups, all of which are optionally substituted. Substituted alkyl groups include fully halogenated or semihalogenated alkyl groups, such as alkyl groups having one or more hydrogens replaced with one or more fluorine atoms, chlorine atoms, bromine atoms and/or iodine atoms. Substituted alkyl groups include fully fluorinated or semifluorinated alkyl groups, such as alkyl groups having one or more hydrogens replaced with one or more fluorine atoms. An alkoxy group is an alkyl group linked to oxygen and can be represented by the formula R-O. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy and heptoxy. Alkoxy groups include substituted alkoxy groups wherein the alky portion of the groups is substituted as provided herein in connection with the description of alkyl groups.

The term "alkenyl" refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having one or more double bonds and to cycloalkenyl groups having one or more rings wherein at least one ring contains a double bond. Alkenyl groups include those having 1, 2 or more double bonds and those in which two or more of the double bonds are conjugated double bonds. Alkenyl groups include those having from 1 to 20 carbon atoms, preferably having from 1 to 12 carbon atoms or 1 to 6 carbon atoms. Alkenyl groups include small alkenyl groups having 2 to 3 carbon atoms. Alkenyl groups include medium length alkenyl groups having from 4-10 carbon atoms. Alkenyl groups include long alkenyl groups having more than 10 carbon atoms, particularly those having 10-20 carbon atoms. Cycloalkenyl groups include those having one or more rings. Cyclic alkenyl groups include those in which a double bond is in the ring or in an alkenyl group attached to a ring. Cyclic alkenyl groups include those having a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-member carbon ring and particularly those having a 3-, 4-, 5-, 6- or 7-member ring. The carbon rings in cyclic alkenyl groups can also carry alkyl groups. Cyclic alkenyl groups can include bicyclic and tricyclic alkyl groups. Alkenyl groups are optionally substituted. Substituted alkenyl groups include among others those which are substituted with alkyl or aryl groups, which groups in turn can be optionally substituted. Specific alkenyl groups include ethenyl, prop-1-enyl, prop-2-enyl, cycloprop-1-enyl, but-1-enyl, but-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, pent-1-enyl, pent-2-enyl, branched pentenyl, cyclopent-1-enyl, hex-1-enyl, branched hexenyl, cyclohexenyl, all of which are optionally substituted. Substituted alkenyl groups include fully halogenated or semihalogenated alkenyl groups, such as alkenyl groups having one or more hydrogens replaced with one or more fluorine atoms, chlorine atoms, bromine atoms and/or jodine atoms. Substituted alkenyl groups include fully fluorinated or semifluorinated alkenyl groups, such as alkenyl groups having one or more hydrogens replaced with one or more fluorine atoms.

The term "aryl" refers to a chemical group having one or more 5-, 6- or 7-member aromatic or heterocyclic aromatic rings. An aromatic hydrocarbon is a hydrocarbon with a conjugated cyclic molecular structure. Aryl groups include those having from 4 to 30 carbon atoms, preferably having from 6 to 18 carbon atoms. Aryl groups can contain a single ring (e.g., phenyl), one or more rings (e.g., biphenyl) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl). Heterocyclic aromatic rings can include one or more N, O, or S atoms in the ring. Heterocyclic aromatic rings can include those with one, two or three N, those with one or two 0, and those with one or two S, or combinations of one or two or three N, O or S. Aryl groups are optionally substituted. Substituted aryl groups include among others those which are substituted with alkyl or alkenyl groups, which groups in turn can be optionally substituted. Specific aryl groups include phenyl groups, biphenyl groups, pyridinyl groups, and naphthyl groups, all of which are optionally substituted. Substituted aryl groups include fully halogenated or semihalogenated aryl groups, such as aryl groups having one or more hydrogens replaced with one or more fluorine atoms, chlorine atoms, bromine atoms and/or iodine atoms. Substituted aryl groups include fully fluorinated or semifluorinated aryl groups, such as aryl groups having one or more hydrogens replaced with one or more fluorine atoms. Aryl groups include, but are not limited to, aromatic group-containing or heterocylic aromatic group-containing groups corresponding to any one of the following benzene, 20 naphthalene, naphthoquinone, diphenylmethane, fluorene, fluoranthene, anthracene, anthraquinone, phenanthrene, tetracene, naphthacenedione, pyridine, quinoline, isoquinoline, indoles, isoindole, pyrrole, imidazole, oxazole, thiazole, pyrazole, pyrazine, pyrimidine, purine, benzimidazole, 25 furans, benzofuran, dibenzofuran, carbazole, acridine, acridone, phenanthridine, thiophene, benzothiophene, dibenzothiophene, xanthene, xanthone, flavone, coumarin, azulene or anthracycline. As used herein, a group corresponding to the groups listed above expressly includes an aromatic or 30 heterocyclic aromatic radical, including monovalent, divalent and polyvalent radicals, of the aromatic and heterocyclic aromatic groups listed above provided in a covalently bonded configuration in the compounds of the present invention. Aryl groups optionally have one or more aromatic 35 rings or heterocyclic aromatic rings having one or more electron donating groups, electron withdrawing groups and/ or targeting ligands provided as substituents.

Arylalkyl groups are alkyl groups substituted with one or more aryl groups wherein the alkyl groups optionally carry 40 aryl groups and more specifically where R is methyl, ethyl, additional substituents and the aryl groups are optionally substituted. Specific alkylaryl groups are phenyl-substituted alkyl groups, e.g., phenylmethyl groups. Alkylaryl groups are alternatively described as aryl groups substituted with one or more alkyl groups wherein the alkyl groups option- 45 ally carry additional substituents and the aryl groups are optionally substituted. Specific alkylaryl groups are alkylsubstituted phenyl groups such as methylphenyl. Substituted arylalkyl groups include fully halogenated or semihalogenated arylalkyl groups, such as arylalkyl groups having one 50 R, is a hydrogen or an alkyl group or an aryl group and more or more alkyl and/or aryl having one or more hydrogens replaced with one or more fluorine atoms, chlorine atoms, bromine atoms and/or iodine atoms.

As used herein, the term "alkylene" refers to a divalent radical derived from an alkyl group or as defined herein. 55 Alkylene groups in some embodiments function as attaching and/or spacer groups in the present compositions. Compounds of the present invention include substituted and unsubstituted C_1 - C_{30} alkylene, C_1 - C_{12} alkylene, C_2 -Cis alkylene, C_5 - C_{12} alkylene, C_7 - C_{12} alkylene and C_1 - C_5 60 alkylene groups. The term "alkylene" includes cycloalkylene and non-cyclic alkylene groups.

As used herein, the term "cvcloalkylene" refers to a divalent radical derived from a cycloalkyl group as defined herein. Cycloalkylene groups in some embodiments func- 65 tion as attaching and/or spacer groups in the present compositions. Compounds of the present invention include sub-

stituted and unsubstituted C_1 - C_{30} cycloalkenylene, C_1 - C_{12} cycloalkenylene and C1-C5 cycloalkenylene groups.

As used herein, the term "alkenylene" refers to a divalent radical derived from an alkenyl group as defined herein. Alkenylene groups in some embodiments function as attaching and/or spacer groups in the present compositions. Compounds of the present invention include substituted and unsubstituted C1-C20 alkenylene, C1-C12 alkenylene, C6-C18 alkenylene, $C_5 - C_{12}$ alkenylene, $C_7 - C_{12}$ alkylene, and $C_1 - C_5$ alkenylene groups. The term "alkenylene" includes cycloalkenylene and non-cyclic alkenylene groups.

As used herein, the term "cycloalkenylene" refers to a divalent radical derived from a cylcoalkenyl group as defined herein. Cycloalkenylene groups in some embodiments function as attaching and/or spacer groups in the present compositions.

Optional substitution of any alkyl, alkylene, alkenyl, alkenylene, and aryl groups includes substitution with one or more of the following substituents: halogens, --CN. -COOR, -OR, -COR, -OCOOR, -CON(R)₂, $-OCON(R)_2$, $-N(R)_2$, $-NO_2$, -SR, $-SO_2R$, $-SO_2N$ (R)₂ or —SOR groups. Optional substitution of alkyl groups includes substitution with one or more alkenyl groups, aryl groups or both, wherein the alkenyl groups or aryl groups are optionally substituted. Optional substitution of alkenyl groups includes substitution with one or more alkyl groups, aryl groups, or both, wherein the alkyl groups or aryl groups are optionally substituted. Optional substitution of aryl groups includes substitution of the aryl ring with one or more alkyl groups, alkenyl groups, or both, wherein the alkyl groups or alkenyl groups are optionally substituted.

Optional substituents alkyl, alkylene, alkenyl, alkenylene, and aryl groups include among others:

-COOR where R is a hydrogen or an alkyl group or an aryl group and more specifically where R is methyl, ethyl, propyl, butyl, or phenyl groups all of which are optionally substituted;

-COR where R is a hydrogen, or an alkyl group or an propyl, butyl, or phenyl groups all of which groups are optionally substituted;

-CON(R)₂ where each R, independently of each other R, is a hydrogen or an alkyl group or an aryl group and more specifically where R is methyl, ethyl, propyl, butyl, or phenyl groups all of which groups are optionally substituted; R and R can form a ring which may contain one or more double bonds:

 $-OCON(R)_{2}$, where each R, independently of each other specifically where R is methyl, ethyl, propyl, butyl, or phenyl groups all of which groups are optionally substituted; R and R can form a ring which may contain one or more double bonds:

 $-N(R)_2$ where each R, independently of each other R, is an alkyl group, acyl group or an aryl group and more specifically where R is methyl, ethyl, propyl, butyl, or phenyl or acetyl groups all of which are optionally substituted; or R and R can form a ring which may contain one or more double bonds.

-SR, -SO₂R, or -SOR where R is an alkyl group or an aryl groups and more specifically where R is methyl, ethyl, propyl, butyl, phenyl groups all of which are optionally substituted; for -SR, R can be hydrogen;

-OCOOR where R is an alkyl group or an aryl groups; $-SO_2N(R)_2$ where R is a hydrogen, an alkyl group, or an aryl group and R and R can form a ring;

—OR where R is H, alkyl, aryl, or acyl; for example, R can be an acyl yielding —OCOR* where R* is a hydrogen or an alkyl group or an aryl group and more specifically where R* is methyl, ethyl, propyl, butyl, or phenyl groups all of which groups are optionally substituted.

Specific substituted alkyl and alkylene groups include halo groups, including trihalomethyl groups and specifically trifluoromethyl groups. Specific substituted aryl groups include mono-, di-, tri, tetra- and pentahalo-substituted phenyl groups; mono-, di-, tri-, tetra-, penta-, hexa-, and 10 hepta-halo-substituted naphthalene groups; 3- or 4-halosubstituted phenyl groups, 3- or 4-alkyl-substituted phenyl groups, 3- or 4-alkoxy-substituted phenyl groups, 3- or 4-RCO-substituted phenyl, 5- or 6-halo-substituted naphthalene groups. More specifically, substituted aryl groups 15 include acetylphenyl groups, particularly 4-acetylphenyl groups; fluorophenyl groups, particularly 3-fluorophenyl and 4-fluorophenyl groups; chlorophenyl groups, particularly 3-chlorophenyl and 4-chlorophenyl groups; methylphenyl groups, particularly 4-methylphenyl groups, and 20 methoxyphenyl groups, particularly 4-methoxyphenyl groups.

As used herein, the term "halo" refers to a halogen group such as a fluoro (—F), chloro (—Cl), bromo (—Br) or iodo (—I).

As to any of the above groups which contain one or more substituents, it is understood, that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible. In addition, the compounds of this invention include all stereochemical ³⁰ isomers arising from the substitution of these compounds.

Overview

In the post-genomics era, a comprehensive analysis of 35 "proteoforms" that arise from genetic variations and posttranslational modifications (PTMs) is essential for understanding biological systems at a functional level toward deciphering disease mechanisms as well as identifying key diagnostic markers and new therapeutic targets. Bottom-up 40 and top-down mass spectrometry (MS)-based proteomics are powerful methods to comprehensively characterize proteoforms to decipher the PTM codes together with sequence variations. However, protein solubility remains a major challenge in bottom-up and top-down proteomics and it is 45 critical to develop MS-compatible surfactants that can quickly degrade into innocuous non-surfactant byproducts prior to MS analysis.

The present application reports the discovery and development of photo-cleavable anionic surfactants, particularly 50 4-hexylphenylazosulfonate (Azo) and sodium 4-hexylphenylazosulfonate, which can be rapidly degraded upon electromagnetic irradiation (e.g., UV radiation), for biological and chemical applications such as top-down proteomics. Azo can effectively solubilize proteins with performance 55 comparable to SDS and is compatible with mass spectrometry analysis, including top-down and bottom-up analysis.

For instance, in experiments Azo-aided top-down proteomics has allowed the detection of 100-fold more unique proteoforms as compared to controls and enabled the solubilization of membrane proteins for comprehensive characterization of post-translational modifications. It is believed the surfactants described herein are the first MS-compatible cleavable surfactants developed for top-down proteomics.

As described below, a library of anionic surfactants was 65 synthesized with a cleavable linker between the hydrophilic head and hydrophobic tail. In some experiments, swine heart

tissue was homogenized twice in HEPES buffer and once in a surfactant solution. The resulting protein extract was separated by SDS-PAGE and stained with Coomassie blue. The leading surfactant, based on the highest concentration of extracted proteins, was tested for MS-compatibility by directly infusing an ubiquitin-surfactant solution into the mass spectrometer to evaluate signal suppression. Finally, the heart protein extract was separated by reversed-phase liquid chromatography (RPLC), infused into the mass spectrometer (Buker maXis II QTOF) via ESI, and fragmented using collisionally activated dissociation (CAD) yielding sequence information and identifications using MASH Suite Pro with TopPIC.

After screening the cleavable surfactant library, one surfactant (referred as "Azo") was identified as the most effective solubility agent. SDS-PAGE analysis and Bradford Assay demonstrated that the Azo surfactant extracted proteins at a similar level to SDS. Furthermore, Western blot analysis confirmed the extraction of common cardiac membrane proteins such as phospholamban, voltage-dependent anion-selective channel, cadherin, and sodium-potassium adenosine triphosphatase. It was observed, by UV-Vis spectroscopy, that Azo degraded rapidly (30-150 s) under various solvent conditions (i.e. aqueous, organic, neutral pH, low pH), making it amenable to high-throughput TDP. In addition, it was verified that the surfactant was compatible with ESI-MS analysis of Ubiquitin while other anionic surfactants like SDS completely suppressed the signal.

The biological application of this technology was demonstrated by evaluating surfactant-aided swine heart tissue lysate using RPLC-MS/MS. The tissue was first homogenized in HEPES to deplete water-soluble proteins in order to evaluate the surfactants ability to increase the proteome coverage. Many unique protein masses (663) were observed that were not present without surfactant. Furthermore, a number of proteins and their PTMs (including acetylation, methylation, phosphorylation, and palmitoylation) were able to be identified using online RPLC-MS/MS. Overall the data was reproducible for sample replicates and could be applied to a number of systems to ameliorate the technical challenge associated with solubilizing intact protein species. The characterization of hydrophobic membrane proteins such as phospholamban and ATP synthase subunit C along their respective PTMs was particularly promising. This technology is also able to probe the membrane proteome including PTMs of plasma membrane proteins. Overall the results demonstrate the surfactant is compatible with a range of proteins with various physiochemical properties and sizes (online identification of proteins as large as 55 kDa) and can assist in clinically relevant studies as well as global proteome analysis if coupled to multidimensional separation methods.

EXAMPLES

Example 1—Synthesis and Characterization of Azo

In an approach, a library of surfactants was designed with a photo-cleavable moiety between the hydrophobic tail and the hydrophilic head aiming for rapid, controlled cleavage and subsequent loss of surface activity (Tehrani-Bagha et al., 2007, Current Opinion in Colloid & Interface Science, 12: 81-91). Specifically, O-nitrobenzyl (ONB), O-nitroveratryl (ONV), and azobenzene (AZO) groups were chosen as linkers because of their rapid degradation kinetics (Bradley et al., 2006, Langmuir, 22: 101-105; Kim et al., 2006, Bioorg Med Chem Lett, 16: 4007-4010; Yan et al., 2013, Journal of the American Chemical Society, 135: 8382-8387; Hwang et al., 2016, Langmuir, 32: 3963-3969; and Hwang et al., 2016, Langmuir, 32: 3963-3969). The properties of the most widely used biological surfactant, SDS, was mimicked by using a sulfonate head for the hydrophilic portion to maxi-5 mize protein solubility (Prive et al., 2007, Methods, 41: 388-397). Various chain lengths were synthesized to optimize the hydrophilic-lipophilic balance character of the surfactants.

After the synthesis and characterization (see Schemes 1-3, 10 and FIGS. 7 and 8), the surfactants with poor water solubility such as ONB surfactant series (C=8, 10, 12) from the library (see Table 1, below) were excluded from further screening. The performance of soluble surfactants such as AZO (C=8, 6) and ONV (C=8, 10, 12) were then evaluated in extracting proteins from tissue extracts since tissues present the most significant challenge for protein solubilization (Chang et al., 2015, Journal of Proteome Research, DOI:10.1021/pr5012679; and Kim et al., 2014, Nature, 509: 575-581). Specifically, the surfactants were used to extract proteins from an "insoluble" cardiac tissue pellet after homogenizing cardiac tissue first in HEPES buffer to deplete soluble proteins. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were employed for sideby-side comparison of protein concentration after the surfactant-aided extraction. Overall, AZO (C=6), referred to as 25 "Azo", was demonstrated to be the top-performing surfactant which is not only water-soluble but also can effectively solubilize proteins from the insoluble tissue pellet (Table 1, below).

The structure of Azo was characterized and verified with ³⁰ high-resolution Fourier transform ion cyclotron resonance (FTICR)-MS in the negative ion electrospray ionization (ESI) mode as well as NMR (FIGS. **7** and **8**). Notably, Azo was simple to synthesize, requiring only two steps (FIG. **1**, panel c), and could be effectively purified using recrystallization, making it an ideal candidate for general use as a surfactant in biological and chemical applications. For instance, Azo was used instead of SDS to perform polyacrylamide gel electrophoresis (PAGE) (Table 4), which demonstrates that Azo could be used as a SDS replacement in SDS-PAGE (FIG. **9**).

The Azo6 surfactant was further characterized using UV-Vis spectroscopy to monitor the photo-degradation of the surfactant into 4-hexylphenol, 4-hexylbenzene, nitrogen, and hydrogen sulfate (Chang et al., 2015, J Proteome Res, 14(3): 1587-99) (see FIG. 1, panel b) upon irradiation with ⁴⁵ a 100 W high pressure mercury lamp for 0, 10, 30, 60, 90, and 120 s using UV-Vis spectroscopy (FIG. **2**, panel a). Several degradation conditions were compared (i.e., organic vs. aqueous solutions in the presence or absence of acid and reducing agents) to determine the most favorable conditions (FIG. **11**). It was observed that the presence of organic solvent and acid facilitates rapid degradation of 0.1% Azo (FIG. **1**, panel b).

The effectiveness of Azo for solubilizing proteins from cardiac tissues was then investigated with a direct side-byside comparison with the strongest surfactant, SDS, and its acid-labile mimic, MasDeS which has shown comparable performance as SDS in protein solubilization (Chang et al., 2015, Journal of Proteome Research, 14: 1587-1599), as well as dodecyl β -D-maltoside (DDM), a commonly used surfactant for native MS. As demonstrated in the SDS-gel (FIG. **2**, panel b) and protein assay with ionic detergent compatibility (FIG. **2**, panel c), the addition of 0.5% Azo to the extraction buffer, E3(Azo), drastically improved the solubilization of proteins, as compared to the control, E3 (NS), which barely solubilize proteins after the depletion of soluble proteins in HEPES extractions, E1 and E2. Overall, the anionic surfactants, Azo, SDS, and MaSDeS, are highly effective in solubilizing proteins compared to the non-ionic surfactant, DDM (FIG. **2**, panels b and c). For the protein solubility experiment (FIG. **2**, panel c) comparing Azo, SDS, DDM, and MaSDeS, three independent protein assays (n=3) were performed to evaluate surfactant performance Error bars represent standard error of the mean.

Furthermore, a Western blot analysis confirmed the presence of common cardiac membrane proteins such as cadherin, sodium-potassium adenosine triphosphatase (Na—K-ATPase), voltage-dependent anion-selective channel protein 1 (VDAC1), phospholamban (PLN), mitochondrial import receptor subunit (TOM20) in the Azo extraction, E3 (Azo), demonstrating the successful extraction of integral membrane protein by Azo as compared to the control, E3 (NS) (FIG. **10**).

Assessing the MS-compatibility of Azo. After demonstrating that Azo could effectively extract proteins from tissues, the MS-compatibility of Azo was then examined First, a standard protein, Ubi, was analyzed by dissolving the protein in a solution of 0.1% surfactant and 80% isopropanol, 14.9% water, 5% formic acid in the direct infusion mode of ESI/MS without any additional desalting step. The results showed the presence of SDS (0.1%) completely suppressed of MS signal and 0.1% MasDeS greatly suppressed MS signal even after degradation in acid condition. On the other hand, 0.1% DDM and 0.1% Azo (after rapid degradation under UV irradiation) had relatively comparable signals showing minimal signal suppression compared to a control sample without surfactant (FIG. 2, panel d). Thus, it was concluded that among all the surfactants screened, Azo6 effectively solubilized proteins band was also compatible with MS analysis of intact proteins.

LC-MS analysis of standard proteins was performed to examine the effect of the UV degradation on MS analysis of proteins. It has been shown that UV irradiation alone did not introduce any adducts or cause any alteration to the protein mass spectrum (FIG. 12). Subsequently, it was demonstrated that the inclusion of reducing agent, TCEP, could successfully minimize the oxidative modifications resulting from exposure of the proteins to the radicals generated upon photolysis of the surfactant or heating at room temperature (FIG. 13).

Alternatively, free methionine could be added to minimize oxidation modification and preserve biologically relevant modifications such as disulfide and glutathionylation (FIG. 14). It was also observed that the usage of Azo had nearly no effect on the relative quantitation of intact proteins from a cardiac tissue lysate by reversed-phase liquid chromatography (RPLC)-MS (FIG. 15). Three separate samples (n=3) were prepared for each condition. Error bars represent standard error of the mean.

Comparison with other leading surfactants. Next, a systematic comparison of Azo with other commonly used surfactants in protein solubilization was performed based on the ability to solubilize proteins from the insoluble cardiac tissue pellets (similarly as described above). MS-compatibility using both standard proteins and tissue lysates was then subsequently assessed (FIGS. **20** and **21**). Overall this broader comparison confirmed Azo's unique ability in effectively solubilize proteins without interfering with downstream MS analysis (FIG. **25**).

The surfactants used for comparison include non-ionic surfactants, Octyl β -D-glucopyranoside (OG) and dodecyl β -D-maltoside (DDM), digitonin (DGT), as well as anionic, acid-labile surfactants, RapiGestTM (RG), ProteaseMaxTM (PM), and MS-compatible slowly-degradable surfactant (MaSDeS) (Chang et al., 2015, Journal of Proteome Research, 14: 1587-1599), together with SDS and Azo6. Nonionic saccharide surfactants such as DDM and OG can be MS-compatible when used at lower concentration (0.01-

0.1%) but they are considered to be relatively mild with limited solubilization ability (Loo et al., 1994, Protein Sci, 3: 1975-1983; and Speers et al., 2007, Chemical Reviews, 107: 3687-3714). On the other hand, anionic surfactants such as SDS and acid-labile SDS mimics have much stron-5 ger surfactants which are capable of solubilizing and denaturing proteins with high efficiency (Speers et al., 2007, Chemical Reviews, 107: 3687-3714). Acid-labile surfactants are developed for improving in-gel or in-solution digestion efficiency for bottom-up proteomics (Chang et al., 2015, 10 Journal of Proteome Research, 14: 1587-1599).

Utilizing SDS-PAGE and Bradford protein assay analysis. It was observed that anionic surfactants including SDS, MaSDeS, PM, RG, and Azo6 showed drastically better protein solubilization ability than the non-ionic surfactants, 15 OG, DDM and DGT (FIG. 16). In particular, Azo effectively extracted proteins at a level similar to SDS, comparable to MasDes, and slightly better than RG and PM (FIG. 16). Data presented were based on three independent experiments (n=3). Error bars represent standard error of the mean.

20 Subsequently, a comparison of the MS-compatibility of Azo with these leading surfactants was performed (FIG. 17). The mass spectrometry analysis of Ubi in the presence of 0.1% surfactants, showed that SDS and MasDeS dramatically suppressed the MS signal of the intact Ubi, RG and PM significantly suppressed the MS signal of Ubi, whereas Azo 25 and non-ionic surfactants, OG, DDM, and DGT showed minimal MS protein signal suppression. Noticeably, these non-ionic surfactants caused more extensive adducts as compared to Azo (FIG. 17).

Example 2-Photo-Cleavable Surfactant for **Top-Down Proteomics**

The utility of Azo for top-down proteomics was assessed in online RPLC-MS and RPLC-MS/MS experiments with 35 collision-induced dissociation (CID). Water-insoluble cardiac tissue pellets were extracted with 25 mM NH₄HCO₃ buffer either containing 0.5% Azo, labelled as E3 (Azo), or no surfactant, served as a control and labelled as E3 (NS) (FIG. 3, panel a). Notably, both the SDS-PAGE gel (FIG. 2, panel b) and the total ion current (FIG. 3, panel b) showed significant increases in protein concentration and MS signal, respectively, with the use of Azo when compared to no surfactant (NS). Moreover, a total of 2836 proteoforms was detected based on accurate mass measurements from the combination of three LC-MS runs; among which 388 pro-45 teoforms were identified based on one-dimensional online RPLC-MS/MS data representing 171 proteins from mitochondria, nucleus, plasma membrane, cytoskeleton, endoplasmic reticulum, cytoplasm, and extracellular regions (FIG. 4).

Importantly, various PTMs included acetylation, methylation, phosphorylation, and palmitoylation were observed. In addition to the breadth in the increased protein identifications, Azo also greatly improved the depth of the detection and revealed many proteins that were undetectable in the 55 control sample (FIG. 19). For example, for the first time, Azo allowed for the detection and identification of an intact calsarcin-1 (CS1; M_r 29961.98) (FIG. 19), an important Z-disk protein that was not detected in the control and not reported previously (Peng et al., Mol. Cell. Proteomics, 2014, 13: 2752-2764). Moreover, multiple phosphorylated proteoforms were detected for CS1. As a negative regulator of calcineurin signaling in heart, CS1 has multiple phosphorylations that are regulated during cardiac hypertrophy (Paulsson et al., 2010, J. Mol. Cell. Cardiol., 48: 1206-1214). Therefore, Azo opens up the opportunity to investi- 65 gate intact CS1 and its phosphorylated proteoforms in cardiac disease.

Membrane Proteomics. Given the critical role of surfactant in the extraction and characterization of peripheral and integral membrane proteins, the effects of Azo on membrane proteomics were further evaluated. It was observed that the optimal degradation condition, with the organic solvent at low pH, also aided in the continued solubilization of hydrophobic species post-degradation. In particular, it was observed that isopropanol or a mixture of isopropanol and acetonitrile effective maintained protein solubility (both hydrophobic and hydrophilic) after degradation. Furthermore, CID fragmentation was highly efficient and favorable for the transmembrane domain portions of the proteins, leading to confident protein identification of integral membrane proteins.

To demonstrate Azo's general applicability to membrane proteomics, a protein extraction was performed using a sarcoplasmic reticulum-mitochondria enriched sample from both cardiac tissue and Human Embryonic Kidney (HEK) 293T cells (FIGS. 5, 10 and 20). Under optimal UVdegradation conditions (which included organic solvent at low pH), many hydrophobic proteins were soluble post Azo-degradation. Using RPLC-MS, 38 subunits of the electron transport chain were identified, including 11 of the 15 ATP synthase subunits, and 18 proteins with transmembrane domains (TMD) from the cardiac tissue. A particularly intriguing integral membrane protein identified in this study was phospholamban (PLN, Mr 6,118.31 Da), receptor-expressing enhancing protein (Mr 21279.93 Da), and succinate dehydrogenase cytochrome b560 (Mr 15279.20 Da) with 1, 2, and 3 transmembrane domains (TMD), respectively (FIG. 30 5, panels a and b, and FIG. 22). Notably, it was detected that PLN is palmitoylated and its palmitoylated proteoform (M, 6,356.54 Da) is highly abundant (FIG. 5). The palmitoylation modification was confidently localized to cysteine 36 within the transmembrane region based on the unmodified b_{33} ion and the palmitoylated b_{38} ion (FIG. 5, panel a, and FIG. 23). PLN is a well-known cardiac regulatory protein which has been implicated in cardiomyopathy (MacLennan et al., 2003, Nat Rev Mol Cell Biol, 4: 566-577) and the palmitovlation (Zhou et al., 2015, Proc Natl Acad Sci USA, 112: 15666-15671) governs its interaction with PKA and protein phosphatase 1a. Similarly, a receptor-expressing enhancing protein was characterized and localized an acetylation site to the N-terminus (FIG. 5, panel b).

Importantly, 46 subunits of the electron transport chain were confidently identified and 51 proteins with TMDs directly from cardiac tissue. Notably, all the subunits of the ATP synthase complex can be identified with high mass accuracy directly from cardiac tissue (FIG. 6). This enzyme, which plays a critical role in biological energy metabolism (He et al., Proc. Natl. Acad. Sci., 2018, 115(12): 2988-2993), includes a domain located in the inner mitochondrial membrane (IMS) (e, f, g, ATP6, ATPS, DAPIT, c, 6.8PL) as well as a domain in the mitochondrial matrix (α , β , b, ε , δ , OCSP, F6, d, y). In particular, Azo facilitated the identification of ATP6 (also known as ATP synthase subunit α ; Mr 24952.55) with 6 TMD as well as the localization (lysine 43) of a highly conserved trimethylation between 2 TMD of ATP synthase subunit c (Mr 7645.04 Da) (FIG. 24). The trimethylation was speculated to provide site-specific binding for cardiolipin (Walpole et al., 2015, Mol. Cell. Proteomics, 14: 828-840). Besides the small and intermediate size subunits (<30 kDa), the high molecular weight (>50 kDa) ATP synthase subunits were able to be detected and identified: ÅTP synthase α (Mr 55179.95 Da) and β (Mr 51702.80 Da) with the help of Azo (FIG. 6). Highly efficient CID fragmentation was observed which preferentially cleaved in the transmembrane domain portions of the proteins (FIG. 5, panels a and b, and FIGS. 22-24), leading to confident protein identification of these integral membrane proteins and localization of PTMs in online RPLC-MS/MS experiments. Thus, Azo was able to enable the detection and comprehensive characterization of these important cardiac membrane protein complexes, which opens up new opportunities to uncover their molecular basis in health and disease.

Materials and reagents. All chemicals and reagents were used as received without further purification unless otherwise noted. Sodium nitrate (NaNO3), sodium sulfite (Na₂SO₃), 4-nitrophenyl chloroformate, sodium carbonate, 10 4-n-hexylaniline, 4-n-octylaniline, 4-n-decylaniline, 4-n-do-N-(3-Dimethylaminopropyl)-N'-ethylcarbodecylaniline, diimide hydrochloride (EDC), 4-(bromomethyl)-3-nitrobenacid, octylamine, decylamine, dodecylamine, zoic N-ethyldiisopropylamine (EDIPA), piperidine, 1,4-butanesultone, and anhydrous N,N-dimethylforamide (DMF) N,N, N',N'-Tetramethyl-O-(1H-benzotriazol-1-yl) uronium hexafluorophosphate (HBTU) and dinitrophenylhydrazine (DNP) were obtained from TCI America (Portland, Oreg., USA). Fmoc-photolabile linker was purchased from Advanced Chemtech (Louisville, Ky., USA). Tetrahydro- 20 furan (THF), ammonium hydroxide (NH₄OH), dichloromethane, heptane, acetone, trimethylamine (Et₃N), magnesium sulfate (MgSO₄), sodium carbonate and silica were purchased from Sigma-Aldrich Inc. (St. Louis, Mo., USA).

Extraction solutions were made in nanopure deionized $_{25}$ (DI) Water (H₂O) from Milli-Q water (Millipore, Corp., Billerica, Mass., USA). HEPES, ammonium bicarbonate (NH₄HCO₃), sucrose, sodium fluoride (NaF), phenylmeth-

anesulfonyl fluoride (PMSF), ethylenediaminetetraacetic acid (EDTA), n-dodecyl β-D-maltoside (DDM), octyl β-Dglucopyranoside (OG), sodium dodecyl sulfate (SDS), digitonin (DGT), protease inhibitor cocktail, tri(2-carboxyethyl) phosphine hydrochloride (TCEP), dithiothreitol (DTT), 2-mercaptoethanol (2-ME), ubiquitin from bovine erythrocytes (Ubi), bovine serum albumin (BSA), myoglobin from equine heart (Myo) and cytochrome C (Cytc) from equine heart, ribonuclease A (RNase A) and ribonuclease B (RNaseB) from bovine pancreas were purchased from Sigma-Aldrich Inc. (St. Louis, Mo., USA). ProteaseMax™ (PM) was obtained from Promega (Fitchburg, Wis., USA). RapiGestTM (RG) was purchased from waters (Milford, Mass., USA). Sodium orthovanadate, HPLC grade H2O, acetonitrile (ACN), methanol (MeOH), ethanol (EtOH), optima LC-MS grade formic acid, optima LC-MS grade isopropanol (IPA), Pierce protein-free tris-buffered saline (TBS) blocking buffer, tween 20, and 10 kDa molecular weight cutoff (MWCO) (0.5 mL) centrifugal filters, Coomassie blue R-250, and Dulbecco's modified eagle medium (DMEM) were purchased from Fisher Scientific (Waltham, Mass.). Fetal bovine serum (FBS) was purchased from Life Technologies (Carlsbad, Calif.). Mini-gels (12.5%) for SDS polyacrylamide gel electrophoresis (SDS-PAGE) were prepared in house. MS-compatible degradable surfactant (MasDeS) was synthesized by Promega and provided to us as a gift as described previously (Chang et al., 2015, J Proteome Res, 14(3): 1587-99).

Synthesis of O-nitrobenzyl (ONB) Surfactant Family

Scheme 1. Synthesis of O-nitrobenzyl (ONB) Surfactant Family.



C12: n = 10C8: n = 6C6: n = 4

Synthesis of 4-(hydroxyethyl)-3-nitrobenzoic acid. A solution of 500 mg of 4-(bromomethyl)-3-nitrobenzoic acid (1.92 mmol) and 814 mg of Na₂CO₃ (7.68 mmol) in 16 mL of a mixture of H_2O /acetone 1:1 (v/v) was refluxed for 5 h. The acetone was then evaporated and the resulting solution 5 was washed with 9 mL of diethyl ether. After the wash, the solution was acidified with 18% hydrochloric acid until a precipitate was observed. The product was then extracted with ethyl acetate (3×12 mL). The concentrated organic layer was washed with H₂O (6 mL) and dried over MgSO₄. ¹⁰ The dry organic layer was filtered and concentrated in vacuo to yield 74% of 4-(hydroxyethyl)-3-nitrobenzoic acid as a vellow solid.

Synthesis of intermediate product I (n=10, C12) (Scheme 1). Using a traditional EDC coupling, 270 mg of 4-(hy- 15 droxyethyl)-3-nitrobenzoic acid (1.37 mmol) was reacted with 0.32 mL of dodecylamine (1.37 mmol) to produce 1 (n=10, C12) in a 44% yield.

Synthesis of intermediate product I (n=6, C8) (Scheme 1). Using a traditional EDC coupling, 300 mg of 4-(hydroxy- 20 ethyl)-3-nitrobenzoic acid (1.52 mmol) was reacted with 0.25 mL of octylamine (1.37 mmol) to produce 1 (n=6, C8) in a 19.3% yield.

Synthesis of intermediate product I (n=4, C6) (Scheme 1). Using a traditional EDC coupling, 300 mg of 4-(hydroxy- 25 ethyl)-3-nitrobenzoic acid (1.52 mmol) was reacted with 0.20 mL of hexylamine (1.37 mmol) to produce 1 (n=4, C6) in a 46% vield.

Synthesis of intermediate product IIs (Scheme 1). 7.7 mmol of each intermediate product I was dissolved in 40 mL $^{-30}$ of THF and the solution was cooled to 0° C. While stirring 4-nitrophenyl, chloroformate was slowly added to the THF solution. Then 0.162 mL of pyridine was added dropwise over 20 min and the reaction was stirred for an additional 2 h. The reaction was then filtered. The final product was 35 purified using a silica column that was packed using a solvent of 7:3 ration of heptane:EtOH and an eluting solvent of a ratio of 4:1 heptane:EtOH.

Synthesis of ONB final product (Scheme 1). 0.13 mmol of intermediate product II was dissolved in 2.3 mL of THF. In 40 ously reported procedures (Hwang et al., 2016, Langmuir, a separate container, 0.20 mmols of 3-aminopropane sulfonic acid sodium salt in 0.43 mL of water was added to the THF solution. The reaction was stirred overnight at 50° C. The product was purified using a silica column with a mixture of dichloromethane: MeOH (1:5). The final product 45 confirmed by mass spectrometry:ONB was C_{12} $(C_{24}H_{38}N_3O_8SNa)$, $[M-Na+H+NH_4]^+$: calculated m/z: 547.6, observed m/z: 547.3; ONB C8 (C₂₀H₃₀N₃O₈SNa), $[M-Na+H+NH_{4}]^{+}$: calculated m/z: 491.5, observed m/z: 491.3; ONB C6 (C18H26N3O8SNa), [M-Na+H+NH4]+ cal- 50 culated m/z: 463.5, observed m/z: 463.3.

Synthesis of O-nitroveratryl (ONV) Surfactant Family.

Scheme 2. Synthesis of O-nitrovertaryl (ONV) Surfactant Family.





C10: n = 8 C8: n = 6

60

The ONV surfactants were synthesized following previ-32(16): 3963-9). Briefly, to a solution of Fmoc-ONV COOH (0.57 mmol) and HBTU (0.69 mmol) in 3.5 mL of anhydrous DMF, EDIPA (1.15 mmol) was added drop wise. The solution was cooled on ice and added to a solution of dodecylamine in 0.5 mL of ice-cold EtOH. After stirring for 30 min at 0° C., the mixture was stirred overnight at room temperature (RT). The resulting precipitate was filtered and washed with DMF followed by in vacuo drying. Intermediate product I (n=10, C12) was obtained as an amorphous white powder. Similar procedure were followed for n=8, C10 and n=6, C8 (Scheme 2).

Synthesis of NH₂—ONV—CH₂ (CH₂). CH₃ (Intermediate product II) (Scheme 2). Piperidine was added dropwise to a solution of intermediate product I (0.6 mmol) in 55 anhydrous DMF (3 mL) to reach a final concentration of 2 M. The solution was stirred at RT for 2 h, and then DMF was removed by evaporation. The residual was dissolved in MeOH and the resulting precipitate was removed by filtration. A pale yellow solid was obtained after evaporation of the filtered solution.

Synthesis of Sulfonate-ONV-CH2 (CH2). CH3 (Final product) (Scheme 2). 1,4-butanesultone (2.1 eq, 0.74 mmol) was added to a solution of intermediate product II (1.0 eq. 0.35 mmol) with Et₃N (2.0 eq) in ACN (2 mL) and then the

65 flask was sealed. The mixture was stirred and heated to ~90° C. for 48 h. After removing the solvent by evaporation, a light yellow viscous oil was obtained quantitatively. The oil was suspended in water and a NH₄OH (aq) solution was added dropwise until pH ~8 was reached. The surfactant solutions were centrifuged. The final product was confirmed by ESI-MS. ONV C_{12} ($C_{29}H_{50}N_3O_8SNa$), [M–Na]⁻, calculated m/z: 600.3, observed m/z: 600.3; ONV C10 ($C_{27}H_{46}N_3O_8SNa$), calculated m/z: 572.3, observed m/z: 572.2. ONV C8 ($C_{25}H_{42}N_3O_8SNa$), [M-Na]⁻, calculated m/z: 544.3, observed m/z: 544.2.

Synthesis of the Azobenzene (AZO) Surfactant Family

Scheme 3. Synthesis of the AZO Surfactant Family.



The AZO surfactant family was synthesized following similar procedures as previously described (Mezger et al., 1996, Progress in Organic Coatings, 29(1): 147-157). Spe30

cifically, 4 mmol of 4-n-hexylaniline (n=4, C=6) was stirred in a mixture of 4.8 mL of 10% hydrochloric acid and 8 mL of DI H₂O. Then 4 mmol of NaNO₂, dissolved in 4 mL of cold water, was added dropwise to this solution. During the addition of the NaNO₂ the solution was cooled to 10° C. After the addition was completed (15 min), the solution was stirred for an additional 15 min at 5° C. A similar procedure was carried out for 4-n-octylanilin (n=6, C8). For 4-ndecylaniline (n=8, C10) and 4-n-dodecylaniline (n=10, C12), the solution of 4-n-alkylaniline was heated to 70° C. and then cooled in an ice bath to 10° C. under vigorous stirring. NaNO2 was added dropwise starting at 20° C. and concluded at 10° C., followed by 15 min of stirring at 5° C. For the coupling reaction, the freshly prepared diazonium salt was filtered into a stirring and cooled solution (T=5-10° C.) of 8 mmol of Na₂SO₃ and 12 mmol of Na₂CO₃ in 20 mL of DI H₂O. To complete the precipitation of the surfactant, the solution was refrigerated at 4° C. overnight. The yellow compounds were purified by recrystallization with a yield about 50% and no impurities were detected by NMR. Surfactant solutions were made by gently heating the surfactant at 37° C. then bringing to room temperature after no solid remained. Working concentration were 0.5%-1% in 25 mM NH₄HCO₃. Kraft temperature (a clear 1% surfactant solution) was previously reported at 24.5° C. (Cravatt et al., 2007, Nature, 450: 991).

A high-resolution mass spectrum of 4-hexylphenylazosulfonate ("Azo") (FIG. 7) was taken as follows: A solution of 1% Azo in 25 mM NH₄HCO₃ was diluted 1:100 in ACN $(0.3\% \text{ NH}_{4}\text{OH})$. The sample was directly injected into a 7 T linear ion trap/Fourier transform ion cyclotron resonance (LTQ/FT-ICR) mass spectrometer (LTQ/FT Ultra, Thermo Scientific, Bremen, Germany) with a nano-electrospray ionization (ESI) source (Triversa NanoMate; Advion Bioscience, Ithaca, N.Y.). A voltage of -1.4 kV was applied with 0.3 psi drying gas. Fifty scans were averaged with 5 microscans in a scan. The mass range was set from 100 to 500 m/z. A mass of 269.098 Da was observed which corresponds to the predicted molecular weight (269.096 Da) for this compound using the Isopro software (Yergey et al., 1983, International Journal of Mass Spectrometry and Ion Physics, 52(2): 337-349).

TABLE 1



Surfactant			Water Solubility at RT	Protein Solubility
Na^+ O N	AZO	C6 C8 C10 C12	Soluble Soluble Slightly Soluble Slightly Soluble	Good Fair Poor Poor

Surfactants with o-nitrobenzyl (ONB), o-nitroveratryl (ONV), and azobenzene (AZO) cleavable groups were synthesized with varied chain lengths from 6-14 carbons (C=6-¹⁵ 14). Each synthesized surfactant was evaluated for its solubility in water first. Next the surfactants were used to solubilize swine heart proteins after HEPES buffer was used to deplete the water-soluble species. Overall Azo (C=6) was the only surfactant which not only has excellent solubility in ²⁰ water but can effectively solubilize proteins.

31

Protein extraction. Pig hearts were excised from healthy Yorkshire domestic pigs, snap-frozen in liquid N₂, and stored under -80° C. before use, which was approved by the University of Wisconsin Animal Care and Use Committee. All homogenization and centrifugation steps were performed at 4° C.

Protein extraction from cardiac tissue. The frozen tissue samples (~500 mg) were cut into small pieces and washed 30 with PBS buffer containing protease inhibitors and reducing agent (5 mM DTT, 1 mM PMSF, 1× protease inhibitor cocktail). The tissue was then homogenized in HEPES buffer (25 mM HEPES, 250 mM sucrose, 50 mM NaF, 1 mM PMSF, 2.5 mM EDTA, 1 mM Na₃VO₄, 1 mM PMSF, 35 5 mM DTT, 1× protease inhibitor cocktail) with a Polytron electric homogenizer (model PRO200, Pro scientific, Oxford, Conn.) set to the lowest speed as described previously (Chang et al., 2015, J Proteome Res, 14(3): 1587-99). The homogenate was centrifuged at 211,750×g using Beck- 40 man Ultracentrifuge and a Ti-80 rotor for 1 h. The supernatant after the first HEPES extraction was removed and saved as "E1" extraction. The HEPES extraction was repeated on the resulting pellet and saved as "E2". After the second HEPES extraction, the tissue pellet was suspended in 45 25 mM NH₄HCO₃ and evenly divided into smaller aliquots. In one aliquot, 25 mM NH₄HCO₃ buffer with no surfactant (NS) was used in a 1:1 ratio (homogenate:buffer) and labeled as "E3". In the other aliquots, surfactants (1% in 25 mM NH₄HCO₃) were individually added to the other aliquots in 50 a 1:1 ratio (homogenate:surfactant) and labeled as "E3" following incubation and centrifugation. Protein assays were performed using Pierce 660 nm Protein Assay Reagent with Ionic Detergent Compatibility Reagent for data presented in (FIG. 2, panel c) and BioRad Bradford assay (BioRad) with 55 detergent compatibility (compatible with 0.1% SDS) for data presented in FIG. 16.

Sarcoplasmic reticulum (SR) and mitochondria (Mit) enrichment from cardiac tissue. After cutting around 170 mg of tissue into small pieces, the tissue was homogenized in 60 HEPES buffer (50 mM HEPES, 0.6 M KCl, 250 mM Sucrose, 500 mM NaF, 1 mM PMSF, 2 mM EDTA, 1 mM Na₃VO₄, 5 mM DTT, 25 μ g/mL DGT, 1× protease inhibitor cocktail) with a Polytron electric homogenizer set to the lowest speed (tissue) to deplete soluble proteins as described 65 previously (Wientzek et al., 1991, Journal of molecular and cellular cardiology, 23(10): 1149-63). The homogenate was

centrifuged at 20,000×g using a Thermo Scientific Legend Micro 21R Ultracentrifuge. The supernatant was removed and labeled as "E1". The pellet was suspended in buffer 2 (25 mM NH₄HCO₃, 500 mM NaF, 1 mM PMSF, 2 mM EDTA, 1 mM Na₃VO₃, 5 mM DTT, 25 μ g/mL digitonin, 1× protease inhibitor cocktail) to remove residual proteins and labeled as "E2". The resulting tissue pellet was suspended in 25 mM NH₄HCO₃ and evenly divided into smaller aliquots, centrifuged at 20,000×g, and the supernatant was removed. 25 mM NH₄HCO₃ buffer (NS) or 1% Azo in 25 mM NH₄HCO₃ was added to the aliquots respectively. After incubation, the samples were centrifuged and the supernatant was collected.

50 µL of enriched sarcoplasmic reticulum and mitochondria lysate from cardiac tissue was diluted with 440 µL of 50:48.5:1:0.5 IPA:H2O:formic acid:HFIP and 10 µL of TCEP (1 M). The sample was irradiated for 3 min and concentrated to a final volume of 150 µL MWCO (10 kDa in run 1 or 30 kDa in run 2). Proteins were separated using the following gradient: 0-1 min 5% B, 1-5 min 5-30% B, 5-55 min 30-60% B, 55-57 min 60-95% B, 57-65 min 95% B, 65-67 min 95% B, 67-80 min 5% B. Column temperature was 35° C. For ATP synthase subunit α , a single charge state was isolated and fragmented with 5, 10, 16, 18, 20 eV, respectively, using an isolation window of 3 m/z during targeted CID MS/MS experiments.

Sarcoplasmic reticulum (SR) and mitochondria (Mit) enrichment from cardiac tissue from human embryonic kidney (HEK) 293T cells. Cells were grown on 10 cm plates in DMEM with 10% fetal bovine serum and 1× penicillin/ streptomycin solution at 37° C. and 5% CO₂. Cells, washed twice the PBS, from two 10 cm plates were lysed in 500 μ L, of buffer (10 mM Tris, 2 mM DTT, 1 mM PMSF, 50 µg/mL DGT, 1× protease inhibitor cocktail) using 50 strokes with dounce homogenizer followed by 5 passages through a 27 G needle. Cells were incubated for 10 min on ice, evenly divided into two aliquots, and centrifuged at 1,000×g (4° C.) to remove unbroken cells and the nuclei. The supernatant was mixed with 0.5 mL of sucrose (50%) and centrifuged at 21,000×g (4° C.). The pellet was washed with 1 mL of NH_4HCO_3 (E2). Finally, the pellets were dissolved in 100 µL of Azo (0.5% in 25 mM NH₄HCO₃) or 100 µL of 25 mM NH₄HCO₃ (NS)

50 μ L of enriched endoplasmic reticulum and mitochondria lysate from HEK cells was diluted with 400 μ L of 50% IPA:49% H2O:1% formic acid and 50 μ L of TCEP (1M). The sample was irradiated for 3 min then concentrated and exchanged into 10:10:80 ACN:IPA:1% formic acid in H₂O with a 10 kDa MWCO centrifugal filter. Protein were separated using the following gradient: 0-5 min 20% B, 5-65 min 20-95% B, 65-75 min 95% B, 75-76 min 20% B, 76-80 min 20% B. Column temperature was 50° C.

Whole Cell Protein Extraction from HEK 293T Cells. Cells from one 10 cm plate were washed and harvested in 10

PBS. 200 µL of Azo (1% in 25 mM NH₄HCO₃) was added with 5 mM TCEP, and 1× protease inhibitor cocktail. The cells were incubated on ice and 200 µL of 25 mM NH₄HCO₃ was added with 500 U of benzonase. The samples were centrifuged at 16,000×g and the supernatant was collected.

Cytosolic Protein Extraction from Cardiac tissue. 10 volumes of buffer (10 mM Tris, 500 mM NaF, 2 mM EDTA, 1 mM PMSF, 1 mM Na₃VO₄, 5 mM DTT) was added to swine heart tissue. The sample was homogenized with Teflon homogenizer, centrifuged at 16,000×g, and the supernatant was collected. Protein extract was diluted to a final buffer containing 25% IPA, 25% ACN, 1% formic acid, 100 mM TCEP, and 5 mM NH4HCO3 with or without 0.2% Azo. The sample was irradiated for 3 min and exchanged into a 10% ACN, 10% IPA, with 0.2% formic acid using a 10 kDa MWCO centrifugal filter. Protein were separated using the following gradient: 0-5 min 20% B, 5-30 min 20-65% B, 30-35 min 65% B, 35-36 min 20% B, 36-40 min 20% B. Column temperature was 60° C.

Protein extraction from swine cardiac tissue for surfactant LC-MS comparison. 83.3 mg of swine cardiac tissue was homogenized in 1 mL of buffer (25 mM NH₄HCO₃, 1 mM TCEP, and 1 mM PMSF). After centrifugation at 16,000×g the supernatant was collected and the protein concentration 25 adjusted to 2 mg/mL

SDS-PAGE comparing Azo with SDS, DDM and MaS-DeS. An equal volume (7 µL) of each extraction was subsequently resolved using 12.5% SDS-PAGE with a voltage of 50 V for 30 min and 120 V for approximately 75 min 30 Proteins were visualized using Coomassie Brilliant Blue R-250.

Western blot comparing Azo with SDS, DDM and MaS-DeS. Equal volumes of tissue lysate (10 µL) were loaded and resolved on 12.5% SDSPAGE gels. Proteins were trans- 35 ferred to a PVDF membrane, fast semi-dry blotter (Fisher-Scientific, Waltham, Mass.), using 20 V for 12 h at 4° C. The membrane was placed in a protein-free blocking buffer (Fisher Scientific, Waltham, Mass.) for 1 hour at RT and incubated with primary antibodies for 1.5 h at RT. The 40 degradation. Standard proteins, Ubi, RNase A, Cytc, and membranes were then washed by using TBS with 0.1% tween five times before incubation with the secondary antibodies for 1.5 h (RT). After 5 washes with TBS with 0.1% tween, the membranes were developed using enhanced chemiluminescence detection (Fisher Scientific, Waltham, 45 Mass.).

UV-Vis degradation. 50 µL of 0.05% Azo in (a) H₂O, (b) 1% formic acid, (c) IPA, (d) 1% formic in IPA, (e) 2-ME in H₂O, and (f) 1% formic acid in IPA:H₂O, respectively, were irradiated with 100 W high pressure mercury lamp (Nikon 50 housing with Nikon HB-10101AF power supply; Nikon, Tokyo, Japan) for 0, 10, 30, 60, 90, and 120 seconds in a quartz cuvette. The samples were diluted to a final volume of 1 mL in H₂O. A UV-Vis spectrum was taken from each sample with a Varian Cary 50 UV-Visible spectrophotometer 55 (background correction, medium scan rate, 600-200 nm).

Evaluation of surfactant mass spectrometry compatibility. Ubi was dissolved in buffer containing 80:14.9:5:0.1 IPA: H₂O:formic acid:0.1% surfactant (Azo, SDS, DDM, or MaSDes) with 10 mM DTT. The Azo sample was irradiated 60 for 1 min. The MaSDes sample was degraded for 24 h at RT. The samples were then directly injected into a 7 T linear ion trap/Fourier transform ion cyclotron resonance (LTO/FT-ICR) mass spectrometer (LTQ/FT Ultra, Thermo Scientific, Bremen, Germany) with a nano-ESI sprayer (TriVersa 65 NanoMate; Advion Bioscience, Ithaca, N.Y.). A voltage of 1.4 kV vs the inlet was applied with 0.3 psi drying gas. 50

scans were collected with 5 microscans in one scan. The mass range was set from 600 to 2,000 m/z.

MS compatibility comparison to common surfactants. Ubi was dissolved in buffer containing 75:10:5:10 MeOH:H₂O: formic acid:1% surfactant (MaSDeS, PM, RG, NS, SDS, Azo, OG, DDM, DGT) with 10 mM TCEP. The Azo sample was irradiated for 3 min. The acid-labile surfactants were incubated for 75 min (24 hr for MaSDeS) at 37° C. The samples were then directly injected into a 12 T Fourier transform ion cyclotron resonance (Solarix) mass spectrometer (Bruker Daltonics, Bremen, Germany) with a nano-ESI sprayer (TriVersa NanoMate; Advion Bioscience, Ithaca, N.Y.). A voltage of 1.4 kV vs the inlet was applied with 0.3 psi drying gas. 200 scans were averaged for each sample. The mass range was set from 600 to 2,000 m/z with a 512,000 word transient.

LC-MS compatibility comparison to common surfactants using endogenous cardiac tissue lysate. To 15 µL of swine cardiac protein extract (2 mg/mL) was added 1.5 µL water, 20 6 µL methionine (25 mg/mL), 25 L isopropanol, 5 µL TCEP (100 mM), and 2.5 µL formic acid. The Azo sample was irradiated for 3 min. The acid cleavable surfactants PM and RG (also known as ALS) were incubated at 37° C. for 1 h while MaSDeS was incubated at 37° C. for 24 hr. All samples without (NS) or with the surfactants (MaSDeS, PM, RG, SDS, Azo, OG, DDM, DGT) were buffer exchanged into 10% ACN, 10% IPA, and 1% FA using a MWCO filter $(3 \times 100 \,\mu\text{L})$ and adjusted to the original volume of 50 μL (see Table 2).

TABLE 2

Water	Methi- onine 25 mg/mL	Surfactant 1% in 25 mM NH ₄ HCO ₃	Extract 2 mg/mL	IPA	TCEP 100 mM	Formic acid
1.5 μL	6 µL	5 µL	15 μL	25 µL	5 µL	2.5 μL

Evaluation of the addition of reducing agents during Azo BSA were dissolved in 49.5:49.5:1 H2O:IPA:formic acid and kept on ice until analysis. Samples were irradiated with a 100 w lamp for 3 min 5 µL of sample was injected onto a trap column and eluted with 40:40:20 ACN:IPA:1% formic acid in H₂O after a 5 min wash with 2.5:2.5:95 ACN:IPA:1% formic acid in H2O. 50 mM of DTT, TCEP, and 2-ME were added to each Cytc samples prior to irradiation. Additionally, a sample of Cytc was kept at RT with no reducing agent and irradiated for 3 min with no reducing agent as controls.

Reversed-Phase Chromatography Coupled to Mass Spectrometry. The reversed phase chromatography gradients for various extraction procedures are provided in Table 3. 20 µL of cardiac tissue lysate with or without Azo (referred to as "Azo" or "NS", respectively) was added 116 µL H₂O, 2 µL of hexafluoroisopropanol (HFIP) (5%), 2 µL trifluoroacetic acid (10%), 10 µL TCEP (1 M), 50 µL IPA, 50 µL ACN. Reagents were added slowly and mixed throughout to avoid precipitation. The samples were transferred to a quartz cuvette and irradiated for 3 min using a 100 w high pressure mercury lamp. The resulting samples exchanged into 20% ACN:IPA (1% formic acid) with a 10 kDa MWCO centrifugal filter and adjusted to a final volume of 200 µL.

50 uL of enriched sarcoplasmic reticulum and mitochondria lysate from cardiac tissue was diluted with 440 µL of 50:48.5:1:0.5 IPA:H₂O:formic acid:HFIP and 10 µL of TCEP (1 M). The sample was irradiated 3 min and concentrated to a final volume of 10 µL MWCO (10 kDa).

50 μ L of enriched sarcoplasmic reticulum and mitochondria lysate from HEK cells was diluted with 400 μ L of 50% IPA:49% H₂O:1% formic acid and 50 μ L, of TCEP (1M). The sample was irradiated 3 min, concentrated and exchanged into 10:10:80 ACN:IPA:1% formic acid in H₂O ⁵ with a 10 kDa MWCO centrifugal filter. The final volume was adjusted to 200 μ L.

Cytosolic cardiac protein extract was diluted to a final buffer containing 25% IPA, 25% ACN, 1% formic acid, 100 mM TCEP, and either 0.2% Azo or 5 mM NH₄HCO₃. The sample was irradiated for 3 min and exchanged into a 10% ACN, 10% IPA, with 0.2% formic acid using a 10 kDa MWCO centrifugal filter.

Reversed phase chromatography (RPLC) was performed ¹⁵ with a nanoACQUITY M-Class UPLC system (Waters; Milford, Mass., USA). Mobile phase A (MPA) contained 0.2% formic acid in H₂O, and mobile phase B (MPB) contained 49.9% ACN:49.9% IPA:0.2% formic acid. For each injection, 5 μ L, of sample was loaded on a homepacked 250×0.250 mm, 5 μ m, 1000 Å PLRP-S (Agilent Technology, Santa Clara, Calif., USA) column A constant 4 μ L/min flow rate was used. For the surfactant comparison 10 μ L of sample was loaded onto a 100×0.5 mm, 5 μ m, 1000 Å PLRP-S and separated with a flow rate of 15 μ L/min. ²⁵

TABLE 3

	m s	Mit from EK cells	SR/ HE	SR/Mit from Cardiac tissue		Cardiac tissue			
в	% В	% A	Time (min)	% B	% A	Time (min)	%В	% A	Time (min)
<u> </u>	20	80	0	5	95	0	20	80	0
)	20	80	5	5	95	1	20	80	5
5	95	5	65	30	70	5	40	60	25
5	95	5	75	60	40	55	60	40	65
)	20	80	76	95	5	57	75	25	75
)	20	80	80	95	5	65	95	5	80
			50° C.	5	95	67	95	5	85
				5	95	80	20	80	86
						35° C.	20	80	95 D
									КГ

Reversed phase chromatography gradients for various 45 extraction procedures. Samples eluted from the column were sprayed directly into a maXis II ETD Q-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) for online LC-MS and LC-MS/MS experiments. End plate offset and capillary voltage were set at 500 and 4000 V, respectively. 50 The nebulizer was set to 0.5 bar, and the dry gas flow rate was 4.0 L/min at 220° C. The quadrupole low mass cutoff was set to 600 m/z during MS and 200 m/z during MS/MS. Mass range was set to 200-3,000 m/z and spectra were acquired at 1 Hz for LC-MS runs. For the top three data- 55 dependent LC-MS/MS CID runs, MS/MS spectra were acquired across 200-2,500 m/z at 2-6 Hz with active exclusion after four spectra. Targeted LC-MS/MS CID was performed at 1 Hz after determining the elution time frame from the targeted proteins. All data were collected with OtofCon- 60 trol 3.4 (Bruker Daltonics).

Data were analyzed and processed in DataAnalysis 4.3 (Bruker Daltonics). An msalign file was created using SNAP peak picking algorithm with the following parameters: quality factor: 0.4; S/N: 3; intensity threshold: 500; retention 65 window: 1.5 min. The file contained the following information: precursor mass, precursor charge, precursor mass fol-

lowed by the fragment masses, intensities, and charges. The alignment-based TopPIC was utilized for intact protein identification based on protein spectrum matches searching against the UniProt Sus scrofa (released on Nov. 22, 2017; containing 26817 protein sequences) or Homo sapiens (released on Dec. 20, 2017; containing 20244 reviewed protein sequences) database (Apweiler et al., 2004, Nucleic acids research, 32 (Database issue), D115-9). Fragment mass tolerance was set to 15 ppm. All identifications were validated with statistically significant P and E values (<0.01) and satisfactory numbers of assigned fragment ions (>10). Additionally, all identifications were manually validated us Mash Suit Pro (Cai et al., 2016, Molecular & cellular proteomics: MCP, 15(2): 703-14) and the corresponding MS and MS/MS data were summarized. For ATP synthase α , a single charge state was isolated and fragmented with 5, 10, 16, 18, 20 ev, respectively, using an isolation window of 3 m/z during targeted CID MS/MS experiments. A mass list from the resulting fragment ions was generated and an identification made as described above.

A proteoform map was generated using a data analysis script as followed (1) LC-MS data were averaged every min; (2) deconvoluted using Max Entropy algorithm (Resolution: 80,000; mass range: 5,000-60,000 Da); (3) mass list output generated using SNAP peak picking (quality factor: 0.8, S/N: 3, absolute intensity 1,000). A graphic map was then generated in Microsoft Excel based on the first retention time and the monoisotopic mass.

Statistical analysis. For the protein solubility experiment (FIG. 2, panel c) comparing Azo, SDS, DDM, and MaSDeS, three independent protein assays (n=3) were performed to evaluate surfactant performance. Error bars represent standard error of the mean. For the broader protein solubility comparison (FIG. 16), data presented were based on three independent experiments (n=3). Error bars represent standard error of the mean. For LC-MS analysis (FIG. 15), three separate samples (n=3) were prepared for each condition. Error bars represent standard error of the mean.

Conclusion. In summary, these results demonstrate a generalizable, high-throughput method for ESI-MS analysis of intact proteins utilizing a photo-cleavable surfactant to increase protein solubility and overall throughput. Among all the surfactants that were evaluated, which included a library of photo-cleavable surfactants, acid-labile surfactants and traditional non-ionic and anionic surfactants, Azo was the only strong surfactant capable of effective solubilization of proteins without hindering downstream top-down MS analysis. Notably, Azo can directly address the solubility challenge in top-down proteomics and significantly increase the number of proteins that can be confidently identified in a given run.

This study provides a streamlined method for analyzing intact proteins that are typically difficult to extract which prohibit further MS analysis. Moreover, Azo has the potential to improve global top-down proteomics studies when coupled to multidimensional separation method, combined with complementary fragmentation techniques for comprehensive protein characterization, and with further improvements in data acquisition strategies (Chen et al., 2018, Anal. Chem. 90: 110-127; and Durbin et al., 2014, Anal. Chem. 86: 1485-1492).

Example 3—Systematic Comparison of Azo with Common Surfactants

A systematic comparison of Azo was performed with commonly used surfactants to evaluate their ability to solu25

bilize proteins from the insoluble cardiac tissue pellets (similarly as described above). The surfactants used for comparison include non-ionic surfactants, octyl β-D-glucopyranoside (OG) and dodecyl β-D-maltoside (DDM), digitonin (DGT), as well as anionic, acid-labile surfactants, RapiGestTM (RG) (also known as ALS), ProteaseMaxTM (PM)1, and MS-compatible slowly-degradable surfactant (MaSDeS), together with SDS and Azo. Non-ionic saccharide surfactants such as DDM and OG can be MS-compatible when used at lower concentrations (0.01-0.1%) but they 10 are considered to be relatively mild with limited solubilization ability. On the other hand, anionic surfactants such as SDS and acid-labile SDS mimics are much stronger, capable of solubilizing and denaturing proteins with high efficiency. Acid-labile surfactants were originally developed for 15 improving in-gel or in-solution digestion efficiency for bottom-up proteomics.

Utilizing SDS-PAGE (FIG. 16, panel a) and Bradford protein assay (Bio-Rad) analysis (FIG. 16, panel b), anionic surfactants including SDS, MaSDeS, PM, RG, and Azo, 20 showed drastically better protein solubilization ability than the non-ionic surfactants, OG, DDM, and DGT. In particular, Azo effectively extracted proteins at a level similar to other leading anionic surfactants such as SDS, MaSDeS, RG, and PM.

Subsequently, a comparison of the MS-compatibility of Azo was performed with these leading surfactants (FIG. 17). The mass spectrometry analysis in the presence of 0.1% surfactants, showed that SDS and MaSDeS dramatically suppressed the MS signal of the intact Ubi; RG and PM 30 significantly suppressed the MS signal of Ubi; whereas Azo and non-ionic surfactants, OG, DDM, and DGT showed minimal MS protein signal suppression.

Importantly, a broader comparison on the LC-MS-compatibility of Azo was also performed with other commonly 3 used surfactants using cardiac tissue lysate (FIG. 18). The LC-MS analysis of the lysate with 0.1% surfactants demonstrated great top-down MS-compatibility of Azo, OG, DDM, and to a lesser extent DGT. On the other hand, significant signal suppression was observed in the presence 40 of SDS and all acid cleavable surfactants, PM, RG, and MaSDeS. Overall, these comparison studies have demonstrated Azo's unique ability to effectively solubilize proteins without interfering with downstream top-down MS analysis (FIG. 25).

Example 4-Identification of Proteoforms in **Top-Down** Proteomics

In this study, a total of 2836 proteoforms were detected 50 based on accurate mass measurements from the combination of three LC/MS runs. However, only 388 proteoforms were identified based on one-dimensional online RPLC-MS/MS data representing 171 proteins from mitochondria, nucleus, plasma membrane, cytoskeleton, endoplasmic reticulum, 55 cytoplasm, and extracellular regions (FIG. 4). The low proportion of protein identification is not a result of proteins being modified by UV photolysis reactions or Azo-induced artifactual modification as demonstrated (FIG. 2, panel d, and FIGS. 12-15 and 17-18). Instead, it is a result of the 60 current limitation on protein separation, fragmentation, data acquisition, and identification algorithms in top-down proteomics (Chen et al., 2018, Anal. Chem. 90: 110-127).

Top-down MS is inherently limited in its ability to identify proteins compared to bottom-up proteomics, despite its 65 advantage in offering a deeper understanding of the existing proteoforms. Even though the proteoforms could be detect

based on their distinct accurate molecular masses, the fragments obtained from the online MS/MS are typically limited especially for large proteins, which makes it difficult to unambiguously identify all of the proteins (proteoforms) detected using the currently available database search algorithm (Cai et al., 2017, Anal. Chem. 89: 5467-5475). In particular, a single dimension of separation is not sufficient to achieve large proteoform identification, but does serve to demonstrate the potential of this surfactant to improve protein solubility and overall throughput.

Admittedly, a well-recognized challenge in top-down proteomics is the detection of large proteins due to the exponential decay in S/N in a mass spectrometer as a function of increasing molecular mass (Compton et al., 2011, Anal. Chem. 83: 6868-6874). Top-down mass spectrometry is biased against larger protein species especially when a single dimension of separation is used; thus, the low molecular weight (MW) proteins may show up more readily even if they are in lower abundance.

Furthermore, the relatively lower number of identification could be due to the co-elution problems since only 1DLC is used in this study with limited separation power, which means that lower abundance and higher MW proteins could be insufficiently fragmented in online LC-MS/MS if coeluting with higher abundance and lower MW species. It is expect that the incorporation of multi-dimensional (MD)LC separation of intact proteins reduces the co-elution of proteins, which enables the detection and identification of low abundance and/or high MW proteins towards a deeper proteome coverage (Cai et al., 2017, Anal. Chem. 89: 5467-5475; and Valeja et al., 2015, Anal. Chem. 87: 5363-5371). Nevertheless, the MDLC strategies need significant amount of samples and dramatically longer experiment time than 1DLC (Chen et al., 2018, Anal. Chem. 90: 110-127). Moreover, RPLC could impose some concerns for analyzing hydrophobic proteins (e.g. too much retention on the column), although early work on intact integral membrane proteomics, namely characterization of GPCR (7TMD) bacteriorhodopsin, was performed using a polymeric reversedphase material, PLRP-S, with column heating as described in a previous study (Whitelegge et al., 1998, Protein Sci. 7: 1423-1430)

In this study, the elution of very hydrophobic species, such as ATP synthase subunit c, was observed also using 45 PLRP-S materials with column heating. Notably, ATP synthase subunit c has a gravy score (an amino acid based hydrophobicity scale that is particularly relevant for denatured proteins) of 1.14 when compared to Bacteriorhodopsin, 0.78, which illustrates that highly hydrophobic species can be evaluated using such RPLC method. However other separation modes may improve the analysis of hydrophobic species and it is important to actively investigate other chromatographic modes for membrane protein separation.

Lastly, while potential improvements could be made should complementary dissociation techniques be applied, other dissociation techniques such as ultra-violet photodissociation (UVPD) may have limited improvement over collision-induced dissociation (CID)/higher-energy collisional dissociation (HCD) in terms of the number of protein identifications via online LC-MS/MS and data dependent acquisition mode (Cleland et al., 2017, J. Proteome Res. 16: 2072-2079). For membrane proteins, CID/HCD fragments transmembrane domains particularly well and highly efficient CID fragmentation was observed which preferentially cleaved in the transmembrane in agreement with previous studies (Whitelegge et al., 1998, Protein Sci. 7: 1423-1430; and Skinner et al., 2014, Anal. Chem. 86: 4627-4634). On the other hand, from a protein characterization standpoint, the use of complementary dissociation techniques, such as UVPD, electron transfer dissociation (ETD)/electron capture dissociation (ECD) together with CID/HCD significantly improved sequence coverage and could greatly aid ⁵ proteoform characterization (e.g. labile PTM localization) (Chen et al., 2018, Anal. Chem. 90: 110-127; Cleland et al., 2017, J. Proteome Res. 16: 2072-2079; and Lin et al., 2018, J. Am. Soc. Mass Spectrom 29: 1284-1294). Nevertheless, this generally requires a more targeted approach to accumulate sufficient spectra, which is better suited to implement a targeted proteomics approach addressing a specific biological question.

Therefore, Azo is believed to have the potential to improve global top-down proteomics studies when coupled ¹⁵ to multidimensional separation methods (Valeja et al., 2015, Anal. Chem. 87: 5363-5371; Cai et al., 2017, Anal Chem 89: 5467-5475; and Xiu et al., 2014, Anal. Chem. 86: 7899-7906), complementary fragmentation techniques such as UVPD and ETD/ECD for comprehensive protein character-20 ization (Cleland et al., 2017, J. Proteome Res., 16: 2072-2079; Lin et al., 2018, J. Am. Soc. Mass Spectrom, 29: 1284-1294; and Riley et al., 2016, J. Am. Soc. Mass. Spectrom. 27: 520-531), and with further improvements in data acquisition and identification strategies (Durbin et al., ²⁵ 2014, Anal. Chem. 86: 1485-1492; and Park et al., 2017, Nat. Methods, 14: 909).

Example 5—Photo-Cleavable Surfactant for Bottom-Up Proteomics

Bottom-up proteomics is a widely used technology for characterizing the proteome. The traditional approach to bottom-up uses SDS or urea to extract and denature proteins for enhanced tryptic digestion. These methods require extensive clean-up steps prior to mass spectrometry (MS) analysis. This example presents a high-throughput method for extracting, digesting, and analyzing proteins by tandem MS (LC-MS/MS) using a photo-cleavable surfactant (Azo) that eliminates the need for additional clean-up steps and greatly 40 enhances the speed of digestion. This method enables reproducible protein extraction, digestion, and LC-MS/MS analysis in a highly streamlined fashion.

In particular, Azo is compatible with bottom-up proteomics, provides a robust high-throughput approach for 45 proteomics analysis (FIG. **30**), and significantly enhances protein extraction and enables rapid digestion for bottom-up proteomics (FIG. **31**, panel A).

Rapid degradation, digestion and analysis. To begin with, Azo's ability to facilitate rapid degradation was evaluated. 50 25 μ g of bovine serum albumin (BSA) was digested at 0.1, 0.5, 1, and 2 h in the presence of 0, 0.05, 0.1% Azo. Protein digestion was monitored using SDS-PAGE (FIG. **29**, panel A). Similarly, myoglobin was digested for 1 h in the presences of 0, 0.05, 0.1%, and 0.2% Azo (FIG. **29**, panel B). 55 Rapid protein digest was observed (<0.5 h) using Azo (0.1%) while a sample without Azo remained intact.

Rapid degradation of Azo was further demonstrated by UV-Vis spectroscopy, where the intact surfactant had a maximal absorbance at 305 nm (FIG. **31**, panel B). 50 μ L of 60 0.1% Azo in 25 mM ammonium bicarbonate (ABC) was irradiate for 0, 1, 3, 5 min using a 100 W mercury lamp (Nikon housing with HB-10101 AFT power supply). The sample was diluted with 950 μ L of water and a spectrum was taken using Varian Cary 50 UV-Visible (600 nm-200 nm, 65 background correction, fast scan rate). In aqueous conditions, 0.1% Azo solution degraded rapidly upon UV irra-

diation (FIG. **31**, panels C and D). This facile surfactant removal method makes Azo ideal for rapid sample processing.

Next, Azo-aided in-solution digestion was evaluated. Myoglobin, a globular protein, was digested in-solution without (0%, control) or in the presence of 0.05%, 0.1%, or 0.2% Azo. The efficiency of digestion was assessed by visualization of the remaining intact myoglobin through SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis (FIG. 31, panel E). After 0.5 h of digestion in the absence of surfactant, the intact protein band at ~17 kDa was observed, suggesting poor digestion efficiency. In contrast, only a faint intact protein band was observed in the presence of 0.05% Azo, and no intact protein band was observed in the presence of 0.1% and 0.2% after 30 min of digestion indicating greatly improved digestion efficiency by Azo. Subsequently, a longer digestion time (1 h) was evaluated in the presence or absence of Azo. Even after 1 h digestion, a predominant intact protein band was still observed without Azo, whereas no intact protein was observed in the presence of 0.05%, 0.1%, or 0.2% Azo (FIG. 31, panel F). This is conceivable, since without a denaturing agent (i.e. an anionic surfactant) the enzyme has limited access to the protein backbone. These results indicate Azo facilitates denaturation of the protein, providing efficient digestion.

Next, the Azo-aided (0.1% Azo, 1 h) myoglobin digest was infused for peptide mass fingerprinting analysis without an additional clean-up procedure and an 89% sequence coverage was observed. On the other hand, analysis of the myoglobin sample digested in the absence of surfactant (0% Azo, 1 h) yielded minimal detectable peptides, and the MS signal was largely dominated by the intact protein (FIG. 35). To confirm the rapid rate of enzymatic digestion in the precedence of Azo, a standard mixture of insulin, myoglobin, and carbonic anhydrase was digested with and without Azo. Partially digested insulin and intact myoglobin and carbonic anhydrase were observed without Azo (FIG. 36), while no detectable intact myoglobin or carbonic anhydrase was observed after 1 h of digestion in the presence of 0.1% or 0.2% Azo and only a small amount of intact insulin was observed (FIG. 36). Taken together, these results indicate proteins can be efficiently and rapidly digested (<1 h) in the presence of Azo.

After demonstrating rapid enzymatic digestion using standard proteins, Azo-aided digestion of complex cell lysates was further investigated. Azo was first used to extract proteins from human embryonic kidney 293T (HEK293T) cells. SDS-PAGE analysis demonstrated reproducible extractions for three HEK samples (FIG. 32, panel A). The proteins were digested for 1 h overnight (ON) to determine whether digestion time, the most time-consuming step in the bottom-up proteomic workflow, could be shortened using Azo while maintaining reproducibility. After LC-MS/MS analysis, the data was processed using MaxQuant for labelfree quantification. An intensity-based absolution quantification (iBAQ) (Schwanhausser et al., 2011, Nature, 473: 337) was used as a benchmark for assessment of reproducibility and compared three biological replicates digested for either 1 h or overnight. Overall, 906 and 934 protein were quantifiable in all three replicates using ON digestion (FIG. 32, panel B) and 1 h digestion (FIG. 32, panel C), respectively. Combined, 1556 protein were quantified using an ON digestion and 1569 proteins were quantified using a 1 h digestion. This corresponded to an 81% overlap between the two conditions (FIG. 32, panel D), confirming 1 h is sufficient for effective protein digestion in the presence of Azo. These results further demonstrate the ability of Azo to accelerate the digestion step in the bottom-up workflow.

The applicability of Azo-aided bottom-up proteomics in tissue proteomics is further demonstrated by applying this strategy to the analysis of swine cardiac tissue. Azo was used 5 to extract proteins from three different swine hearts as well as three extraction replicates from one heart and showed high reproducibility for biological and technical extraction replicates by SDS-PAGE analysis (FIG. 33, panel A). Furthermore, LC-MS/MS analysis showed good reproducibility 10 between extraction (FIG. 33, panel B), biological (FIG. 33, panel C), and digestion replicates (FIG. 33, panel D) after trypsin digestion using iBAQ quantification as a benchmark. Using Gene ontology analysis (Ashburner et al., 2000, Nat Genet, 25: 25-29), the major class of proteins involved in 15 metabolic processes, cellular component organization or biogenesis, and cellular processes were observed (FIG. 33, panel E). Most proteins were shown to be catalytic active or binding properties through molecular function sorting (FIG. 33. panel F).

Methods used in the above experiments are described further below.

Digestion and Analysis of Standard Proteins. Myoglobin $(25 \ \mu g)$ was dissolved in 25 mM ABC with 0, 0.05, 0.1, 0.2% Azo (final volume was 50 μ L). 10 μ L was collected before 25 digestion and boiled in SDS loading dye for SDS-PAGE analysis. Trypsin (1:50 enzyme:protein) was added to the remaining myoglobin solution and the sample was incubated at 37° C. 10 μ L was collected at 0.5 h and 1 h, respectively, and boiled in SDS loading dye to quench the reaction. The 30 samples were loaded onto a 10% acrylamide gel, separated with 125 V, and stained with Coomassie blue for visualization (FIG. **31**, panel E).

The remaining digested (1 h, 0-0.2% Azo) myoglobin was analyzed by liquid chromatography-mass spectrometry (LC-35 MS) analysis, the sample was irradiated with UV and the protein was separated on a PLRP column (200×0.25 mm, 10 um, 1000 Å) using 0.2% formic acid in water (A) and ACN:IPA (B) with a 15 min gradient from 20%-80% B. The sample was eluted from the column and infused into maXis 40 II ETD Q-TOF (Bruker Daltonics) using 4500 V and an endplate voltage of 500 V. MS scans were collected at 1 Hz (FIG. **31**, panel D).

Additionally, the digested (1 h, 0.1% Azo) myoglobin was directly infused into a 12T solariXTM Fourier Transform Ion 45 Cyclotron mass spectrometer (Bruker Daltonics) mass spectrometer using a nano-ESI source (Triversa NanoMate; Advion Bioscience, Ithaca, N.Y.). A voltage of 1.5 kV was applied with 0.3 psi drying gas for peptide mass fingerprinting. Scans were collected at 512,000 word with a mass range 50 of 200-3000 m/z. Data were analyzed in Mascot allowing for 2 missed cleavages with oxidation (M) as a variable modification (FIG. **35**).

Finally, 10 μ g insulin, 20 μ g of myoglobin, and 60 μ g of carbonic anhydrase were digested in 0, 0.1, and 0.2% azo for 55 1 hr. After digestion the samples were irradiated with UV and analyzed by LC-MS using a maXis II ETD Q-TOF as described above for myoglobin (FIG. **36**).

Protein Extraction, Digestion, and LC-MS/MS Analysis of HEK293T Cells. Human embryonic kidney (HEK) cells 60 (ATCC, Manassas, Va.) were grown on 10-cm plates with 10% FBS and 1× Penicillin-Streptomycin at 37° C. with 5% CO_2 . Plates (~90% confluent) were washed with PBS, pelleted at 500×g, flash-frozen, and stored at ~80° C.

All steps were performed at 4° C. Cells from a single plate $_{65}$ were lysed with 250 μ L of buffer (0.5% Azo, 25 mM ABC, 5 mM tris(20 carboxyethyl)phosphine (TCEP), 5 mM eth-

ylenediaminetetraacetic acid (EDTA), and 1× Halt protease/ phosphatase inhibitor cocktail) and sonicated for 5 s (at 20% amplitude) to shear the DNA. The extract was centrifuged for 10 min at 16,000×g and the supernatant removed. Protein concentration was determined using BCA protein assay reagent with albumin as a standard. 25 μ g was analyzed by SDS-PAGE.

200 µg of protein (final volume was 50 µL and Azo concentration ~0.1% for digestion) was reduced with 5 mM dithiothreitol (DTT), alkylated with 15 mM iodoacetamide (IAA), and digested with trypsin (1:50) overnight or for 1 h at 37° C. The surfactant was degraded with UV and the reaction was quenched with formic acid. The sample was centrifuged for 5 min at 16,000×g and the supernatant was subsequently collected.

10 μ L samples were loaded onto a home-packed C18 column (250×0.25 mm) and separated using a 60 min gradient from 5-40% B. Mobile phases were 0.2% formic acid in water (A) and ACN (B). The column was heated to 20 60° C. and the flow rate was 5 μ L/min. Peptides eluted from the column were infused into an Impact II Q-TOF mass spectrometer (Bruker Daltonics) using 4500 V and an end-plate voltage of 500 V. MS scans were collected at 2 Hz and the top 30 most intense ions were selected for collision-25 induced dissociation (CID) using a 3 m/z window, 8-32 Hz (intensity 2500-25000) scan rate, and a voltage energy that was determined on the m/z and charge. (FIG. **32**).

Extraction, Digestion, and LC-MS Analysis of Cardiac Proteins. Proteins were extracted from swine cardiac tissue using a one-step Azo extraction. All steps were performed at 4° C. 15-20 mg of cardiac tissue was homogenized in 15 volumes (μ L/mg of tissue) of buffer containing 0.5% Azo, 25 mM ABC, 5 mM dithiothreitol (DTT), 5 mM PMSF, and 1x Halt protease/phosphatase inhibitor cocktail with a polytron electric homogenizer. The homogenates were centrifuged for 30 min at 17,000xg at 4° C. and the supernatant was collected for analysis. Protein concentration was determined using Pierce BCA protein assay reagent with bovine serum albumin as a standard. The extracts were normalized to 2 μ g/ μ L and 20 μ g of the biological and technical extraction replicates were visualized by SDS-PAGE to qualitatively assess reproducibility.

200 µg of protein (final volume 50 µL) was reduced with 5 mM DTT for 30 min at 37° C., and alkylated with freshly prepared 25 mM IAA for 45 min at room temperature in the dark, quenched with 5 mM DTT, and digested with trypsin (1:50) overnight at 37° C. The reaction was quenched with trifluouracetic acid and the surfactant was subsequently degraded with UV light. The sample was sonicated for 10 min and centrifuged for 30 min at 17,000×g at 4° C. and the supernatant collected for LC-MS analysis.

About 4 μ g of peptides were loaded onto a trap column (Waters, 2D Symmetry C18 100 A 5 um 180 um×20 mm), and subsequently separated on an analytical column (Waters, Peptide BEH C18 nanoACQUITY 130 A, 1.7 um, 75 um×200 mm), and heated to 60° C. at a flow rate of 0.3 μ L/min Peptides were separated using a 60-min gradient from 5-45% B. Mobile phases were 0.2% formic acid in water (A) and ACN (B). The column was interfaced with a Bruker Impact II quadrupole-time of flight (Q-TOF) mass spectrometer and ionized via CaptiveSpray with ACN Nano-Booster (FIG. **33**).

Membrane Protein Enrichment, Digestion, and LC-MS Analysis. HEK cells from a single 10-cm plate were lysed with 1 mL of buffer (2% Triton X-114, 25 mM ABC, 25 mM methionine, and 1 mM phenylmethylsulfonyl fluoride). After 1 h incubation at 4° C., cells were centrifuged for 5 min at 16,000×g at 4° C. The supernatant was removed and heated to 37° C. to induce the cloud point (Bordier et al., 1981, J Biol Chem, 256: 1604-1607). The mixture was centrifuged at 3,000×g at room temperature (RT) and the top layer was removed. The bottom triton layer was washed with 5 cold buffer (25 mM ABC and 25 mM methionine) and the cloud point procedure was repeated. The triton layer was precipitated with 4 v of acetone overnight. 0.1% Azo was added to solubilize the precipitated pellet and the sample was briefly sonicated in a water bath. The protein concen-10 tration was determined by BCA assay using BSA as a standard. 100 µg of protein was reduced, alkylated, digested ON, and analyzed as described above (a 90 min gradient from 5-45% was used for LC separation) (FIG. **34**).

Data Analysis. For LC-MS/MS experiments, data was 15 analyzed using MaxQuant (Version 1.5.7.4) searching against the *Homo sapiens* reviewed Uniprot databased (Mar. 12, 2019) or *Sus scrofa* unreviewed (Nov. 27, 2018). A 1% FUR was set for protein and peptide identifications. Carbamiomethylation of cysteine was set for fixed modification 20 while N-terminal acetylation and methionine oxidation were set as variable modification. Two missed cleavages were allowed. All other setting were based on the default parameters for Q-TOF instrument

Additional analysis of cardiac proteins. In addition to the 25 above, about 20 mg of tissue, from 6 swine hearts, was homogenized in 0.5% Azo (FIG. 26). 50 µg of protein were reduced, alkylated, and trypsinized overnight. The samples were irradiated for 3 min with a 100 W mercury vapor lamp to degrade the surfactant. The samples were centrifuged and 30 \sim 4 µg of peptides were loaded onto a C18 column. The peptides were separated (FIG. 27) and analyzed by mass spectrometry. Protein identifications were determined using MaxQuant (FIG. 28). Good reproducibility was observed, using both sodium dodecyl sulfate polyacrylamide gel elec- 35 trophoresis (SDS-PAGE) and LC-MS/MS analysis, across tissue replicated using this method. Importantly, no sample clean-up (e.g. solid phase extraction) was required before LC-MS/MS analysis making this method more highthroughput than urea-assisted in-solution digestion or filter 40 aided sample preparation (FASP).

Results. Overall, Azo enabled reproducible extraction, rapid digestion (1 hr), and LC-MS/MS analysis of proteins extracted from cardiac tissue. These results show reproducible Azo-aided tissue proteomics with future application in 45 understanding the molecular mechanism in diseases.

Although Azo significantly facilitates protein extraction of proteins in both cell and tissue samples, a caveat in the use of strong extraction reagents (including SDS) for protein extraction is the resulting complex protein mixture leads to 50 bias against certain protein species. For example, integral membrane proteins, which are hydrophobic and generally expressed at lower levels, are generally underrepresented in proteomics studies (Zhang et al., 2015, Molecular & cellular proteomics: MCP, 14: 2411-2453; and Helbig et al., 2010, J 55 Proteomics, 73: 868-878). In this study, Triton X-114 was used to perform a cloud point extraction to enrich membrane protein from HEK cells with a single extraction (Bordier et al., 1981, J Biol Chem, 256: 1604-1607; and Pavic et al., Biochim Biophys Acta, 1860, 1710-1715). However, Triton 60 surfactants are incompatible with MS analysis and require surfactant removal prior to MS analysis (Loo et al., 1994, Protein Science, 3: 1975-1983). Here, Azo solubilized precipitated protein pellets enriched with integral membranes for a more effective analysis of this important class of proteins. After successfully solubilizing and digesting the protein pellet, 453 integral membrane proteins were

observed in the enriched sample (results from a two LC-MS/ MS experiments), compared to only 184 in the Azo whole cell lysate sample without enrichment (result from combined three LC-MS/MS using 1 hr digestion and three LC-MS/MS using an ON digestion) (FIG. **34**, panel A). Moreover, 29 proteins were identified with 10+ predicted transmembrane domains (TMD)(Krogh et al., 2001, J Mol Biol, 305: 567-580), such as NADH-ubiquinone oxidoreductase chain 5 (15 TMD), verifying Azo can solubilize and aid in the digestion of highly hydrophobic species (FIG. **34**, panel B).

This example demonstrates that Azo is compatible with bottom-up proteomics without an additional clean-up step after UV degradation of the surfactant, and that the use of Azo drastically accelerates the rate of enzymatic digestion. Importantly, Azo enables highly reproducible protein digestion results within only 1 h for high-throughput bottom-up proteomic analysis of cell and tissue lysates. Considering that protein digestion is the most time-consuming step in bottom-up proteomics and is generally performed for >9 h to ensure high digestion efficiency (Link et al., 1999, Nature Biotechnology, 17: 676; and Proc et al., 2010, Journal Proteome Research, 9: 5422-5437), shortening this step in the workflow without loss of digestion efficiency would dramatically improve sample throughput, permitting bottom-up analyses to a wide range of applications especially those require high-throughput analysis in clinical diagnostics. Moreover, an Azo-aided bottom-up workflow is developed for effective solubilization of membrane proteins for high-throughput membrane proteomics. Overall this technology could greatly improve the bottom-up workflow where digestion is typically performed overnight making it more viable as a clinical diagnostic tool. Taken together with the additional experiments described above, the present example shows the unique utility of Azo as an "all-in-one" MS-compatible surfactant for both top-down and bottom-up proteomics, with streamlined workflows for high-throughput proteomics amenable to clinical applications.

Example 6—Photo-Cleavable Surfactant for Extracellular Matrix Proteomics

The extracellular matrix (ECM) provides an architectural meshwork for surrounding cells. It plays a critical role in cancers, regenerative medicine and cardiovascular diseases, where the composition and organization contribute greatly to disease progression. Mass spectrometry (MS) is an ideal methodology to profile proteome changes and promote further understanding of ECM biology. It is therefore critical to develop robust, universal strategies to facilitate analysis of this important class of proteins to develop better therapeutics. However, the current protocols for MS analysis of the ECM are challenging due to extremely poor solubility of the ECM, long labor intensive workflows including multiple digestions and offline sample clean-up of MS incompatible reagents. To address these challenges, a novel, high-throughput strategy for ECM proteomics was developed using a photo-cleavable, anionic surfactant (Azo). Azo greatly improves the solubility of the ECM, facilitates effective, quick enzymatic digestion without the need for harsh chemical reagents, and requires minimal sample cleanup for a user-friendly bottom-up mass spectrometry-based characterization method.

Decellularization, ECM Protein Extraction, Digestion and RPLC-MS/MS. Frozen left and right ventricle tissue from human and swine hearts were harvested and flash frozen in accordance with the University of Wisconsin-Madison Institutional Review Board. Additionally, polyomavirus middle T (PyVT) transgenic, metastatic breast cancer mouse tissue was removed and flash frozen in accordance with the University of Wisconsin-Madison animal use and care committee. A rotor stator homogenizer (Pro Sceintific Inc.) was used to homogenize the sample of ice in 2% Triton X-100 or 5 LiCl for tissue decellularization. Following centrifugation at $16,100 \times g$ at 4° C. for five minutes, the remaining pellet was washed with ammonium bicarbonate, centrifuged again, and the supernatant was discarded. The pellet was washed a total of five times to remove the Triton X-100 and any residual 10 soluble proteins. Next, the insoluble tissue pellet was homogenized in 0.5% Azo extraction buffer (FIG. **37**).

The protein concentration was determined with a BCA protein assay using Albumin as a standard. 140 µg of protein was then reduced with 10 mM dithiothreitol (DTT) and 15 alkylated with 25 mM iodoacetamide and digested with trypsin at a 1:50 enzyme:protein concentration. The reaction was quenched with formic acid and UV-irradiation with a 100 W mercury lamp was used to rapidly degrade the surfactant. Approximately, 30 µg of peptides were separated 20 using a C18 column with 0.2% formic acid in Water and ACN as mobile phase A and B respectively. Eluted peptides were electrospray into a Bruker Impact II (ESI-QUAD-TOF) for MS analysis. Top 30 most intense peaks were selected for collisionally activated dissociation (CAD). Pep- 25 tide spectral matching was performed against MS/MS spectra with Mascot (Ver. 2.5) against UniProt databases (Homo sapiens downloaded Jun. 16, 2015, Mus musculus downloaded May 4, 2018 and Sus scrofa downloaded Jun. 27, 2013) and the following parameters; two missed cleavages 30 of trypsin; peptide precursor tolerance of 0.6 Da and MS/MS tolerance of 0.3 Da.; variable modifications: N-terminal acetylation, carbamidomethylation of cysteine, methionine oxidation, deamidation of asparagine and hydroxylation of proline. MaxQuant (1.7.5.4) was used with two missed 35 cleavages of trypsin; variable modifications: N terminal acetylation, carbamidomethylation of cysteine, methionine oxidation, deamidation of asparagine and hydroxylation of proline. All other settings were set to the default.

SDS-PAGE. Laemmli buffer supplemented with 100 mM $_{40}$ DTT was added to decellularization and Azo extracts. Samples were boiled at 97° C. for 3 minutes and separated at 155 V on an in-house cast 8% polyacrylamide gel.

Offline high-pH reverse-phase fractionation. Following trypsin digestion, 100 µg of Azo extraction was transferred 45 to an equilibrated Thermo ScientificTM PierceTM High pH Reversed-Phase Peptide Fractionation Kit spin column. Peptides were bound under aqueous conditions and a step gradient of increasing concentrations of acetonitrile (5-50%) was used elute bound peptides into eight fractions according 50 to the manufactures instructions. Fractions were left unpooled or pooled (#1&5, 2&6, 3&7, 4&8). Fractions were dried in a vacuum centrifuge, reconstituted in 0.2% formic acid, and analyzed by LC-MS/MS as stated above.

Development of robust, reproducible sample preparation 55 method for decellularization and solubilization of ECM proteins. First, a decellularization strategy was developed to purify the ECM by depleting cellular material and decreasing sample complexity thus allowing for the detection of lower abundance proteins. ECM proteins and ECM-associated proteins are challenging to solubilize, enzymatically digest, and in some cases are relatively lower abundance compared to cellular proteins, which prevents their identification of ECM using a traditional bottom-up approach. The present approach first homogenizes tissue in LiCl or Triton 65 X-100 decellularization buffers for depletion of cellular proteins, followed by extraction of the insoluble ECM

proteins using Azo (FIG. 37). This approach enhances the current lengthy subcellular fractionation kits and traditional multi-day decellularization processes. Good reproducibility was observed, using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, across decellularized and Azo tissue extraction replicates using this method (FIG. 38). Following trypsin digestion and LC-MS/ MS analysis, ECM proteins identified in the Triton, LiCl and Azo extraction fractions were observed. Many soluble proteoglycans and associated extracellular matrix proteins, like Annexins, were observed in both fractions were found in the Triton, LiCl, and Azo fractions while more insoluble fibrous proteins, like Fibrinogen, were only found in the Azo fraction. Notably, the decellularization fractions are often ignored in ECM protocols; however, the present results show solubility of a number of ECM proteins in the decellularization fractions, warranting analysis of both extracts. Some enrichment of the ECM is also seen upon decellularization

Next, it was demonstrated that Azo can facilitate an accelerated digestion time for ECM proteins. 140 μ g of *Sus scrofa* heart Azo extractions were digested with trypsin and quenched the reaction at 1 hour, 2 hours, 4 hours and overnight. The number of Mascot protein identifications from each sample was used as a benchmark for digestion efficiency. A two-hour trypsin digestion yielded optimal results, with no significant increase in ECM protein. This greatly accelerates the time of trypsin digestion, which is typically performed overnight for ECM proteomics. The workflow presented does not include MS incompatible reagents like urea and SDS, removing the need for a desalting step or sample clean-up post-digestion.

Importantly, the Azo-assisted ECM proteomics method addresses several challenges with current ECM proteomics workflows. First, Azo extracts enriched for ECM proteins require no sample clean-up or desalting (e.g., solid phase extractions or precipitation) prior to LC-MS/MS analysis. Elimination of these steps makes this method more highthroughput than traditional protocols utilizing SDS and other MS incompatible detergents. It also eliminates potential steps for sample loss and method irreproducibility. Furthermore, the need for digestion with toxic reagents like cyanogen bromide, multi-enzyme digestions, and overnight digestion protocols is eliminated. Overall, this protocol requires less sample handling, making it particularly userfriendly. ECM proteomics workflows are notoriously lengthy, whereas our protocol is rapid, increasing the throughput. As an estimate, traditional ECM sample preparation protocols for mass spectrometry take several days or even weeks. The approach described in this example provides an effective, high-throughput workflow that can easily be completed in a day.

Offline high-pH fractionation coupled to RPLC-MS/MS for global ECM proteomics. For a more global coverage, digestions were fractionated using an offline high-pH fractionation prior to online RPLC-MS/MS. Fractionation reduced the overall sample complexity and improving the ability to identify low-abundant peptides and ECM proteins (FIG. **40**). Pooling was accessed to determine if a large difference was seen in ECM protein identifications. A pooled approach yielded the largest number of identifications. Importantly, the separation takes fifteen minutes with a benchtop centrifuge, whereas other multi-dimensional separations often collect a large number of fractions and subsequently a lot of instrument time is needed. Overall, the spin

50

filter approach still enables similar coverage and significantly saves time on downstream LC-MS analysis time.

Azo Enabled Characterization of ECM proteome. ECM proteins from both core matrisome and associated divisions were identified. In addition, ECM proteins from all major 5 classes including glycoproteins, proteoglycans, collagens, regulated, secreted and ECM affiliated proteins were cataloged. Lists were compiled for several one dimensional and two-dimensional LC-MS/MS analyses of mouse tumor extractions, providing a resource for targeted analysis. The 10 Azo enabled ECM proteomics workflow also allows simultaneous profiling of proteins of interest ECM remodeling and disease progression seen in both cardiovascular disease and cancer. The method provides a simple, simultaneous approach to monitor additional proteins from other cellular 15 locations that may interact downstream. String analysis reveals the expected enrichment of GO pathways involved in ECM mediated biological processes. A protein-protein interactome String analysis revealed expected enrichment of GO pathways involved in ECM mediated biological pro- 20 cesses. A protein-protein interactome revealed aggregated networks of identified proteins in ECM organization, cellmatrix adhesion, and cell-substrate adhesion functional cellular processes. Relevant interactions within the network provide new directions for future experimental pathways of 25 interest.

Conclusions. Although bottom-up proteomics is a widely used technology for characterizing the proteome, there are only very few published methodologies for ECM proteomics mainly due to the difficulty in solubilizing and digesting 30 ECM proteins. The demand for new, user-friendly methodologies is seen with the increasing understanding and importance of the ECM in disease progression and development. However, the lack of user-friendly ECM proteomics methodologies is currently hindering analysis of this important 35 sub-proteome. Current methods predominately suffer from the use of MS incompatible reagents including SDS or urea to solubilize the matrix. These methods also require timeconsuming digestions and extensive clean-up steps prior to mass spectrometry (MS) analysis that can lead to sample 40 loss. The best type of approach will depend on the particular proteins and tissue of interest as ECM composition can vary widely. This is the first demonstration of ECM proteomics utilizing the novel use of a photo-cleavable surfactant (Azo). The method enables reproducible protein extraction, diges- 45 tion, and LC-MS/MS analysis in a highly streamlined fashion. In summary, the ECM pipeline presented here has broad applicability for utilization in studies pertaining to multiple types of diseased tissues and sites.

Example 7—Photo-Cleavable Surfactant as a Substitute for Sodium Dodecyl Sulfate in Gel Electrophoresis

Given surfactants are instrumental in biological and bio-55 medical research, it is envisioned that the photo-cleavable surfactants of the present invention will play an essential role in a myriad of proteomic studies, including those with clinically relevance. Additionally, the photo-cleavable surfactants of the present invention also can be used as a 60 cleavable SDS-replacement in general biochemical applications, notably, in gel electrophoresis.

SDS-PAGE. As described above, an equal volume (7 μ L) of each extraction was subsequently resolved using 12.5% SDS-PAGE with a voltage of 50 V for 30 min and 120 V for 65 approximately 75 min. Proteins were visualized using Coomassie Brilliant Blue R-250.

Azo-PAGE. Similarly, gel electrophoresis was performed using Azo instead of SDS. The general electrophoresis conditions were as follows (see also Table 4 below): Azo Loading Dye (2x): 100 μ L Tris (1M pH 6.8), 10 mg Azo, 200 μ L, Bromophenol blue (0.04% solution), 200 μ L glycerol, 20 μ L DTT (1M). Volume adjusted to 1 mL with water. Azo running buffer: 1.5 g Tris Base, 7.2 g Glycine, 2.5 g Azo. Adjusted to 1 L with water. 2.5 μ g of BSA, β -casein, and RNase A or 10 μ g of cardiac myofilament extract (Peng et al., 2014, Proteomics Clin Appl, 8: 554-568) was then separated on a 1 mm, 12.5% polyacrylamide gel run at 150V.

TABLE 4

Composition of Acrylamide Gel for SDS/Azo-PAGE.						
	5 mL Resolving	2 mL Stacking				
Water 30% Acryalmide 1.5M Tris 1M Tris 10% APS	1.62 mL 2.09 mL 1.25 mL 0 mL 0.05 mL	1.42 mL 0.33 mL 0 mL 0.25 mL 0.02 mL				
TEMED	0.003 mL	0.002 mL 0.002 mL				

FIG. 9 shows the results of polyacrylamide gel electrophoresis (PAGE) using Azo (panels a and b) and SDS (panels c and d). Azo-PAGE analysis of (a) 2.5 μ g bovine serum albumin (BSA), β -casein, and ribonuclease A (RNase A), and (b) myofilament cardiac tissue protein extract with Coomassie blue staining. SDS-PAGE analysis of (c) 2.5 μ g BSA, β -Casein, and RNase A, and (d) myofilament cardiac tissue protein extract with Coomassie blue staining. As seen in FIG. 9, Azo-PAGE was able to produce comparable results to SDS-PAGE.

Having now fully described the present invention in some detail by way of illustration and examples for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the art that the same can be performed by modifying or changing the invention within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope of the appended claims.

When a group of materials, compositions, components or compounds is disclosed herein, it is understood that all individual members of those groups and all subgroups thereof are disclosed separately. Every formulation or combination of components described or exemplified herein can be used to practice the invention, unless otherwise stated. Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. Additionally, the end points in a given range are to be included within the range. In the disclosure and the claims, "and/or" means additionally or alternatively. Moreover, any use of a term in the singular also encompasses plural forms.

As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the

45

claim. Any recitation herein of the term "comprising", particularly in a description of components of a composition or in a description of elements of a device, is understood to encompass those compositions and methods consisting essentially of and consisting of the recited components or 5 elements.

One of ordinary skill in the art will appreciate that starting materials, device elements, analytical methods, mixtures and combinations of components other than those specifically exemplified can be employed in the practice of the invention 10 without resort to undue experimentation. All art-known functional equivalents, of any such materials and methods are intended to be included in this invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention 15 that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. The invention illustratively described herein suitably may be 20 practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Headings are used herein for convenience only.

All publications referred to herein are incorporated herein to the extent not inconsistent herewith. Some references 25 provided herein are incorporated by reference to provide details of additional uses of the invention. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated 30 by reference herein in their entirety to indicate the state of the art as of their filing date and it is intended that this information can be employed herein, if needed, to exclude specific embodiments that are in the prior art.

The invention claimed is:

1. A method of solubilizing and analyzing a compound comprising the steps of:

- a) mixing the compound with a photo-cleavable surfactant in a solution until the compound is dissolved in the 40 solution,
- wherein the photo-cleavable surfactant comprises: i) a hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail; and
- b) exposing the solution containing the photo-cleavable surfactant and dissolved compound to electromagnetic radiation, thereby decomposing the photo-cleavable moiety; and
- c) performing mass spectrometry (MS) analysis on a 50 portion of the solution exposed to the electromagnetic radiation and containing the compound for both top-down and bottom-up proteomics.

2. The method of claim **1**, wherein the solution containing the photo-cleavable surfactant and dissolved compound is 55 exposed to ultraviolet (UV) light.

3. The method of claim **2**, wherein the UV light has a wavelength between 250-350 nm.

4. The method of claim **1**, wherein the compound is a digested or undigested protein or polypeptide.

5. The method of claim **1**, comprising separating components in the solution using a chromatography step and exposing the solution containing the dissolved compound to electromagnetic radiation before injecting the dissolved compound into a mass spectrometer, wherein the separating 65 step, exposure step, and injection into the mass spectrometer occurs in real time.

6. The method of claim 1, comprising exposing the solution containing the dissolved compound to electromagnetic radiation within a mass spectrometer during ultraviolet photo-dissociation (UVPD).

7. The method of claim 1, wherein the solution comprises an organic solvent, aqueous solvent, or combinations thereof, wherein the solution further comprises 10% or less of an acid or reducing agent.

8. The method of claim **1** wherein the solution comprises 1% or less of the photo-cleavable surfactant.

9. The method of claim 1, wherein the photo-cleavable surfactant has the formula



where n is an integer selected from 2 to 30.

10. The method of claim **9**, wherein where n is an integer selected from 6, 8 or 10.

11. The method of claim **1**, wherein the photo-cleavable surfactant is 4-hexylphenylazosulfonate or sodium 4-hexylphenylazosulfonate.

12. A method of solubilizing a compound comprising the steps of:

- a) mixing the compound with a photo-cleavable surfactant in a solution until the compound is dissolved in the solution,
- wherein the compound is a digested or undigested protein or polypeptide, and
- wherein the photo-cleavable surfactant comprises: i) a hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail; and
- b) exposing the solution containing the photo-cleavable surfactant and dissolved compound to electromagnetic radiation, thereby decomposing the photo-cleavable moiety.

13. The method of claim 12, wherein the solution con-taining the photo-cleavable surfactant and dissolved compound is exposed to ultraviolet (UV) light.

14. The method of claim 12, wherein the solution comprises an organic solvent, aqueous solvent, or combinations thereof, wherein the solution further comprises 10% or less of an acid or reducing agent.

15. The method of claim **12** wherein the solution comprises 1% or less of the photo-cleavable surfactant.

16. The method of claim 12, wherein the photo-cleavable surfactant has the formula



where n is an integer selected from 2 to 30.

17. The method of claim **12**, wherein the photo-cleavable surfactant is 4-hexylphenylazosulfonate or sodium 4-hexylphenylazosulfonate.

18. A method of solubilizing a compound comprising the steps of:

- a) mixing the compound with a photo-cleavable surfactant in a solution until the compound is dissolved in the solution,
- wherein the photo-cleavable surfactant comprises: i) a hydrophilic head, ii) a hydrophobic tail, and iii) a photo-cleavable moiety covalently linking the hydrophilic head and hydrophobic tail; and
- b) exposing the solution containing the photo-cleavable surfactant and dissolved compound to electromagnetic radiation, thereby decomposing the photo-cleavable moiety,

wherein the photo-cleavable surfactant has the formula:



5 19. The method of claim 18, wherein the solution containing the photo-cleavable surfactant and dissolved compound is exposed to ultraviolet (UV) light.

20. The method of claim **18** wherein the solution comprises 1% or less of the photo-cleavable surfactant.

* * * *